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1.1. Leishmaniasis 
 
1.1.1. Definition  
In 1903 Leishman and Donovan described first the occurrence of later called Leishman-
Donovan bodies in splenocytes of diseased patients in India (57, 119). The first described 
patient was affected by attacks of pyrexia, anaemia, and enlargement of the spleen 
wherein the amastigote form of the later called Leishmania donovani parasite was found 
(15). Nowadays several different Leishmania species are known, which are transmitted by 
sandflies of the genus Phlebotomus [Old World] and Lutzomyia [New World] and cause a 
variety of clinical symptoms collectively known as leishmaniasis. 
 
 
1.1.2. The parasite 
Protozoan parasites from the genus Leishmania are the causing agent of the disease 
leishmaniasis. These parasites belong to the Kingdom Protista, Subkingdom Protozoa, 
Phylum Sarcomastigophora, Subphylum Mastigophora, Class Zoomastigophora, Order 
Kinetoplastida, Family Trypanosomatidae, Section Salivaria. The Order Kinetoplastidae is 
determined by a characteristic structure called the kinetoplast that extends to a single large 
mitochondrion harboured by unicellular organisms, whereupon trypanosomes also belong 
to this group. Most forms of leishmaniasis are transmitted via sandflies from a rodent or 
mammal reservoir to the human host, whereas in Bihar, India, humans are the sole known 
reservoir for visceral leishmaniasis (200). In total, 20 out of 30 species can cause human 
infections. 
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The  natural  life  cycle  of  Leishmania parasites  comprises  two  forms  which  are  
morphologically distinguishable. In the female phlebotomine sandfly the promastigotes 
form can be found. These parasites possess a flagellum, have an elongated cell 
morphology and are motile. Seven to ten days after the uptake and transformation from the 
amastigote stage to the promastigote stage in the sandfly gut the parasites move to the 
proboscis and can be injected into the host subcutaneously during a blood-meal. 
In contrast, the amastigote form of Leishmania parasites found intracellular has a roundish 
morphology, no flagellum and is not motile. As an obligate intracellular parasite, it infects 
neutrophils, macrophages [MΦ], dendritic cells [DC] and fibroblasts of the mammalian 
host (34, 211). These parasitized cells can be taken up during a blood meal. 
Experimental evidence suggests a continuous progression in the developmental cycle 
between amastigote and promastigotes in nature (151). 
 
 
human skin
sandfly gut
promastigote
intracellularly
amastigote
 
 
Fig. 1: Leishmania life cycle. Main characteristics of the Leishmania life cycle are the transformation from 
the amastigote stages into promastigote stages in the sandfly gut and vice versa intracellularly in the 
mammalian host. 
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1.1.3. The clinics 
Cutaneous, mucocutaneous and visceral leishmaniasis are together with viscerotropic 
leishmaniasis the three major forms of the disease. Additionally, cutaneous manifestations 
can be further differentiated into diffuse leishmaniasis, leishmaniasis recidivans, localized 
leishmaniasis, and post-kala-azar dermal leishmaniasis. 
The manifestation of localized cutaneous leishmaniasis [CL] is largely depending on the 
immune status of the host and varies depending on the stage of disease. The bite of a 
sandfly usually takes place at exposed areas of the skin, e.g. hands, face and legs. There, 
lesions develop beginning with a red papule which may have several centimetres in size. 
In later stages the lesion is crusting, shows granuloma formation and the development of 
an  erythematous  rim.  The  self-healing  of  this  form  can  take  two  to  twelve  months  and  
leaves  scars  with  changes  in  pigmentation.  In  contrast,  in  anergic  patients  diffuse  
cutaneous leishmaniasis [DCL] can develop that is accompanied by formation of plaques, 
ulcers  and  nodules  all  over  the  body.  This  infection  is  chronic  and  may  recur  after  
treatment, which is most common in New World species but also for L. aethiopica in the 
Old World. The re-occurrence of lesions at the border or the centre of healed lesions 
[scars] is termed leishmaniasis recidivans. This can start years after the initial infection 
and is often resistant to treatment. Instead, post-kala-azar dermal leishmaniasis [PKDL] is 
the dermal re-occurrence of the disease after recovery from visceral leishmaniasis and had 
predominantly been described in Africa and India. Cases in India describe the formation 
of multiple, hypopigmented, erythematous macules years after the recovery from the 
initial affection. This form needs severe treatment whereas the less harmful African form 
spontaneously resolves within several months (84, 191). 
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The mucocutaneous form of leishmaniasis [ML] is commonly seen in the New World 
while  cases  of  ML  in  the  Old  World  are  only  reported  for  L. aethiopica infections. 
Initially, infections start with persistent cutaneous lesions which could be self-healing. 
Although, in 30% of the cases no infection with Leishmania parasites were reported prior 
to the outbreak of ML. Years later, oral and respiratory mucosal involvement occurs, 
causing inflammation and mutilation of the nose, mouth, oropharynx, and trachea with 
granula formation, ulceration and erosion of the palate, uvula, lips, pharynx, and larynx. 
Deformities occurring in time, especially of optical and genital mucosa in severe cases, 
need plastic surgery. Due to the fact that this form is difficult to treat, these disabilities can 
lead to death via malnutrition and secondary airway infections (84, 191). 
Visceral leishmaniasis, also known as kala-azar or black fever, causes the most severe 
symptoms and leads to death if left untreated, due to immunosuppression and secondary 
infections.  The  disease  results  from both,  New World  as  well  as  Old  World  species  and  
 
Fig. 2: Clinical presentations of leishmaniasis. A: cutaneous leishmaniasis, B: mucocutaneous 
leishmaniasis, C: visceral leishmaniasis. 
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causes the pentad of fever, weight loss, hepatosplenomegaly, pancytopenia, and 
hypergammaglobulinemia due to the systemic infection of the liver, spleen and bone 
marrow (84, 191). 
 
 
1.1.4. Epidemiology 
According to reports of the world health organistion [WHO], 88 countries in intertropic 
and temperate regions of the world are endemic for leishmaniasis and in total 350 million 
people are at risk. Each year an estimate of 500,000 cases of visceral leishmaniasis occur 
mainly [90%] in Bangladesh, Brazil, India, Nepal and Sudan. Accordingly, an estimate of 
1.5 million cases of cutaneous leishmaniasis occur yearly, mainly [90%] in Afghanistan, 
Brazil, Iran, Peru, Saudi Arabia and Syria. In the Old World - meaning the Middle East, 
Indian subcontinent, Asia, Mediterranean, East Africa, and republics of the former Soviet 
Union, these cases are caused by the species L. tropica, L. major, L. aethiopica, L. 
donovani and L. infantum.   In  the  New  World  -  throughout  the  Americas,  with  the  
exception of Canada, Chile, and Uruguay - species like L. Leishmania mexicana, L. 
Leishmania amazonensis, L. Leishmania venezuelensis, L. viannia braziliensis, L. viannia 
guyanensis, L. viannia panamensis, L. viannia peruviana and L. donovani chagasi cause 
the diverse types of leishmaniasis. 
Primarily people of tropical and subtropical countries which are considered as developing 
or under-developed countries are affected. Although, a large number of cases in the 
European Mediterranean and, increasingly, also in Germany were reported (80, 144) the 
disease is found within the list of neglected tropical diseases. 
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Of major concern are actually co-infections of Leishmania with  HIV.  According  to  the  
WHO, respective cases have already been reported for more than 35 countries throughout 
southern Europe, the Mediterranean Basin, Central and South America, and India. As 
previously diseased people who recovered from leishmaniasis are not sterile and AIDS 
 
 
Fig. 3: Distribution of Phlebotomine sandflies and cases of autochthonous leishmaniasis  
in Germany (144). 
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leads to immunosuppression, re-occurrence and opportunistic infection with Leishmania is 
increasing in countries which are endemic for both (6). 
 
Regarding the three major forms of leishmaniasis different numbers for mortality or 
morbidity have to be mentioned. CL mostly resolves within 3-6 months, whereas most 
cases of DCL, PKDL and leishmaniasis recidivans are associated with low mortality rates, 
chronic disease and resistance to treatment. ML is chronic as well as progressive and can 
lead to death because of secondary infection. VL has a mortality rate of 75-95% if left 
untreated. In this case, death usually occurs from malnutrition and secondary infection if 
the diseased people would have not been treated. 
Normally, the age of a person itself is not decisive for a certain risk of getting infected, but 
changes of habits and behaviour which occur during life time may influence the specific 
risk. Exceptionally, a higher prevalence for VL is found for children in endemic areas with 
an animal reservoir. Regarding the gender, males have an increased incidence of infection 
[2:1] due to increased exposure to the habitat of the sandfly (191). 
 
 
1.1.5. Experimental leishmaniasis 
Leishmania spp. cause infections in a variety of animals. Naturally occurring infections of 
these animals are hard to recognize, as in these animals only minor to no symptoms can be 
detected. In contrast, infections of humans and dogs often have severe implications. But, 
in epidemiological terms, humans and dogs may be considered as secondary or accidental 
hosts in the Leishmania’s life-cycle (64). With regard to this situation the choice of an 
animal model is difficult and has to be applied to the individual goal (87). 
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Several experimental animal models of leishmaniasis have been established to study the 
pathogenesis and pathology of leishmaniasis, the impact of chemotherapy or the 
preventive effect of vaccines against the agents causing CL and VL (64, 81). Studies in 
mice, hamsters, dogs and non-human primates were carried out especially to determine the 
efficacy of chemotherapy and vaccination in consecutive steps. Whereas an early model 
using guinea pigs showed the relevance of cell mediated immunity [CMI] for the 
clearance of Leishmania parasites (36), the most prominent animal model for this disease 
is the mouse model due to the feasibility of genetic manipulation. Already since the 70’s it 
was known that the genetic background of inbred mouse strains contributes to the outcome 
of leishmaniasis in the respective mice (79). In contrast to CBA mice or C57BL/6 mice 
BALB/c mice are highly susceptible to infections with different Leishmania spp. including 
L. major (219). Since then, a number of mouse strains have been used as experimental 
models of infection with different Leishmania species including L. major, L. tropica, L. 
mexicana, L. amazonensis, L. donovani, L. infantum and L. braziliensis. The availability 
of different mouse cell surface markers and the respective specific antibodies in 
combination with several dyes and technical improvements allow the assessment of 
immune pathways in wild type and modified animals. The impact of single cell 
populations in the progression of the disease can be monitored comparatively. Since 
different CD4+ T cells and effector cells like CD8+ T cells [cytotoxic T lymphocytes, 
CTL], NK cells and MΦ as well as cytokines like interleukin-4 [IL-4], IL-12, interferon 
gamma [IFNγ] and tumor necrosis factor alpha [TNFα] were known to play a major role in 
the progression of leishmaniasis their influence in shaping the immune response was 
under surveillance.  
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Here, BALB/c mice were used that are highly susceptible to Leishmania parasites. For the 
investigation of vaccine efficacy or to elucidate the mechanism of DC-based vaccination 
mice receive a single vaccination with antigen-loaded cells intravenously [i.v.] and a 
subsequent infection with 2 × 105 metacyclic L. major promastigotes subcutaneously [s.c.] 
into the right footpad. Generally, this is the high dose model for cutaneous leishmaniasis. 
Upon infection naïve BALB/c mice develop lesions that never heal (87, 158). Within the 
lesion the parasites replicate intracellularly in MΦ and in later stages disseminate to 
internal organs. This systemic infection leads to death if left untreated and resembles 
features of visceral leishmaniasis. 
 
 
1.2. The immune system 
The immune system consists of a very complex interplay between different cell types, 
molecules and specialized tissues. In front line the innate immune system responses to 
several pathogens where the complement system as well as cell-dependent clearance of 
cellular and bacterial material is involved. But, some infections need further mechanisms 
due to the pathogenicity or virulence of the causing agent. Therefore an adaptive immune 
response is needed to initiate the expansion and activation of specific effector cells against 
distinct pathogens.  
Of course, this system fails when it is overwhelmed by a high number of pathogens or due 
to a weakened immune status because of the individual age, co-infections or 
immunosuppressive medication. To circumvent these situations we would like to 
strengthen and to teach the immune system ahead of the first encounter of a distinct 
pathogen. Therefore we have to exploit natural resources of the immune system. But, the 
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complexity  of  this  system  first  has  to  be  disclosed  to  understand  how  it  can  be  
manipulated. 
In  this  study  a  focus  was  set  on  major  players  during  the  initial  phases  of  immune  
instruction: DC as inducer of specific responses and T cells as messenger and effector cell 
types. 
 
 
1.2.1. Dendritic cells 
In 1973 Steinman and Cohn (193) first described a stellate cell population, which they 
called dendritic cells. But, cell types relating to these DC were already mentioned earlier 
by Paul Langerhans in 1886 (113). Later on, lots of studies were published, which 
demonstrated the diversity of these DC in terms of function, mode of action, lineage and 
cell-interactions (23, 106, 132, 174, 193). In the following chapters this diversity should 
be disclosed to give an overview about DC properties, which might be important for this 
study. 
 
 
1.2.1.1. Dendritic cell lineages and subsets 
Actually, there is a huge debate about DC lineages and subsets as not every individual DC 
prepared ex vivo resembles  a  specific  subset  and  not  every  common  or  rare  surface  
molecule is a linage marker. Additionally, the well-known plasticity of immune system 
related  cell  types  also  might  play  a  role  for  DC  development  and  differentiation  (161).  
Lots of review articles do exist, which state commonly that DC linage specificity, 
differentiation and function is still an open field to be explored (161, 188). 
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To make the bunch of different DC subsets manageable Shalin H. Naik started to classify 
DC by some general properties (143). First, DC precursors were separated from their DC 
products. Furthermore migratory, resident and circulating DC were distinguished. Their 
presence during steady state or during inflammatory processes was also taken into 
account. Additional criteria have been the respective subtypes and their activation status. 
According  to  the  first  discrimination  argument,  monocytes  and  plasmacytoid  DC [pDC]  
are seen as non-DC antigen-presenting cells [APC] and DC precursors during 
inflammatory responses, which need certain stimuli for the differentiation towards the 
dendritic  phenotype  (188).  pDC are  of  particular  interest  in  this  work  here  and  are  well  
known to produce interferon type I [IPC] upon stimulation via microbial products and 
need  the  same  stimuli  to  differentiate  into  DC  and  to  develop  the  abilities  of  antigen  
processing and presentation (75, 124, 149, 231).  
The next discrimination argument leads to the differentiation between circulating, 
migratory and tissue resident DC. Resident DC are defined as immature DC CD11chi, 
CD45RAlo and major histocompatibility complexint [MHCIIint]  DC,  which  can  further  be  
divided into CD8+ and CD8- DC (143, 222). Associated to them are migratory DC which 
are characterized as DC residing in peripheral tissues until they receive certain signals. 
These signals induce the migration of DC into secondary lymphoid organs and 
additionally,  these signals can induce the maturation of these respective DC towards a T 
cell activating phenotype (166). Quite contrary, other stimuli do not induce this kind of 
maturation, but still induce the migration of DC to lymph nodes in a transforming growth 
factor-beta 1 dependent manner (222, 223). Surprisingly, referring to the third class in this 
category, CD11chi cells cannot be found in significant numbers in the circulation and 
among them there is no T cell activating capacity without further hematopoietic 
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development (150). This finding could argument against the idea of migratory DC in 
“clean” mice, whereas in “dirty” humans blood-DC (128) can be found, which gives rise 
to additional questions about the difference between mice and men. 
Now  the  key  players  in  DC  immunity  have  to  be  classified.  Among  them  there  are  
monocytes, pDC, Langerhans cells, interstitial DC, resident CD8+ and CD8- resident DC. 
As already mentioned, monocytes get recruited to several organs and into the blood stream 
under inflammatory conditions  to act as one part of the innate immune defence against 
pathogens (185). But, it is also known that monocytes can differentiate into macrophages 
or CD11c+ MHCII+ DC to fulfil adaptive immune functions (188). Furthermore, as a 
second pre-DC cell type, pDC are found in many lymphoid organs under steady state 
(143). Here they act as sensors of certain toll-like receptor [TLR] agonists (27, 54, 96, 97, 
189) and produce the well-known type I interferon burst and a wide set of chemokines and 
cytokines upon stimulation (159). The third subclass of DC is called Langerhans cells. 
These cells are high in numbers in the epidermis [2-4%] (113) but their role in adaptive 
immunity and tolerance is not quite clear and still under debate (5, 137, 183, 196, 221, 
233). Langerhans cells and interstitial DC are the main subclasses of human conventional 
DC [cDC] (17, 187). Although these DC are present throughout the body and are thought 
to be involved in immune-regulation there is only little experimental evidence for their 
function during infection (216, 233). At last, CD8+ and  CD8- resident DC are mainly 
found in spleen and lymph nodes whereas they show differential spatial distribution (2, 51, 
135). Their main role in the immune system is related to tolerance (24, 148), the ability of 
cross-presentation (52, 156) and T cell priming during viral and bacterial infections (5, 25, 
52). 
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While applying vaccines i.v. all of these DC subtypes could be involved in anti 
Leishmania vaccination strategies. Therefore the outcome of such a complex immune 
stimulation depends on the immunostimulatory capacity of the respective adjuvant-antigen 
formulation. 
Different naturally occurring subsets of DC can now be pigeonholed. But the residual 
problem is to match these categorized DC with in vivo-generated DC. A first attempt to 
exploit the immunostimulatory capacities of DC was to load ex vivo prepared DC with 
antigen and to activate these DC in parallel to resemble naturally infected, fully activated 
DC. The most common method to generate these DC in vivo - as it is done here in this 
study - is the cultivation of bone marrow-derived cells with medium that is supplemented 
with granulocyte macrophage-colony stimulating factor [GM-CSF]. Here, monocytes and 
other precursors develop into adhering DC. As already mentioned, monocytes are 
recruited and differentiate towards a DC phenotype under inflammatory conditions. 
Therefore bone marrow-derived DC [BMDC] do not necessarily resemble steady state DC 
but inflammatory DC (227). But, here the common abilities of these cells - antigen uptake, 
antigen presentation via MHC class I and II molecules and T cell activation - are exploited 
to lead the immune system towards the favoured direction. 
 
 
1.2.1.2. Properties: antigen uptake and degradation 
The main mechanisms of antigen uptake by DC include macropinocytosis, receptor-
mediated endocytosis and phagocytosis (205). These mechanisms are constitutively active 
at high levels already during an immature stage of the respective DC but can be further 
heightened via activation of DC with microbial stimuli (194, 220). 
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Macropinocytosis  -  from  Greek  “cell  drinking”  -  is  the  constitutive  engulfment  of  large  
entities of extracellular liquids via forming of cell membrane pockets with a diameter of 
0.5-5 µm (60) that allows continuous capture of macrosolutes which are present in the 
liquid phase surrounding the respective cell (177). In addition, phagocytosis - from Greek 
“cell eating” - means the unspecific internalization of  particles, including cell debris, 
which can be larger than 0.75 µm in diameter (129). Third, receptor-mediated endocytosis 
is more specific but is also restricted to a smaller volume. The uptake via clathrin-coated 
pits [or within caveolae] is restricted to a size up to 100 nm and is induced by as 
prominent receptors as the mannose receptor (164, 177) and the Fcγ receptor (7) but also 
by a bunch of other membrane-bound receptors which are specific for self or pathogen-
derived molecules. 
Regarding degradation, every cell produces peptides that can be released into the 
cytoplasm or can be accumulated in vesicles. Therefore mechanisms are needed to 
degrade self-produced mis-folded, damaged or excess antigen in the cytoplasm as well as 
external antigen in vesicles for subsequent use in antigen presentation. These two different 
compartments use different mechanisms for degradation and additionally, these 
compartments are kept separate with the exception of antigen-exchange for cross-
presentation (7). Cytoplasmic proteins get mainly degraded by the ubiquitin-proteasome-
system (229). Here, a complex of 14 subunits is forming the 20S proteasome. The 20S 
proteasome in addition with the 19S regulators forms the 26S proteasome for the ATP-
dependent degradation of ubiquitin-labelled proteins (230). Further more, for the 
formation of the immunoproteasome only three catalytically active subunits have to be 
exchanged for the production of a different spectrum of peptides which can be loaded onto 
MHC molecules. The immunoproteasome is active in almost every immune system-
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related cell type and is inducible in almost all other cell type upon stimulation with IFNγ 
or  TNFα (230).  Differently,  the  degradation  of  external  antigen  accumulated  in  vesicles  
follows an alternative pathway. Here, peptides and proteins become degraded by different 
proteases, especially cathepsins, which degrade external proteins as well as MHC class II 
molecules for the proper presentation on the cell surface (44, 207). Therefore, peptides 
captured from the extracellular environment have to be directed from early endosomes via 
endosome carrier vesicles or multivesicular bodies to late endosomes. Then, depending on 
signals the respective vesicle carries itself, these vesicles either join the pathway for 
complete degradation and peptide re-cycling or the pathway for peptide presentation on 
the surface upon activation of the respective DC (155). 
 
 
1.2.1.3. Properties: antigen presentation 
Maturation of DC and antigen presentation by this potent cell type is closely associated. 
As mentioned above, the specific sequestration of cellular material is dependent on the 
activation status of the cell (31). Likewise, antigen presentation is modified upon DC 
maturation.  
DC mature and get activated upon receptor activation by several ligands/signals which can 
be received on the surface of the respective DC as well as within endocytic vesicles and 
the  cytoplasm.  During  steady  state  the  activation  status  of  DC  is  permanently  under  
influence of several receptors which are able to sense host-derived as well as pathogen-
derived molecules. These receptors are responsible for the determination of the 
surrounding milieu and the discrimination between self and foreign. First, pattern 
recognition receptors [PRR], which are able to sense pathogen associated molecular 
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patterns [PAMP] in forms of peptides, cell wall components, lipopolysaccharides [LPS] 
and nucleic acids like CpG-containing oligodeoxynucleotides [CpG ODN], play a major 
role in the activation of DC and other cell types (95, 98, 165, 208). Furthermore, TLR, a 
prominent family of PRR, can be exploited by some endogenous ‘danger signals’. 
Thereby, the presence of non-self as well as differences between apoptotic and necrotic 
cell material or an overall inflammatory status of the surrounding milieu can be sensed (3, 
20, 69, 182). This inflammatory milieu is generated by epithelial cells, non-hematopoietic 
and hematopoietic cells, which have gradual influence on DC maturation and activation 
(91, 117, 146, 170, 171). Here, pro-inflammatory cytokines like TNFα, type I interferons 
and interleukins like IL-18 play a major role. This enables DC to display the current status 
regarding immunogenic or non-immunogenic situations and to act on subsequent cell-
types in the right manner. Additionally, it was shown that also activated T cells share the 
ability of activating DC at later stages. Therefore direct cell-cell-interaction - including 
cluster of differentiation 40 [CD40]–CD40L interactions - is needed to transmit a signal 
which enables DC to fully activate CTL. 
In the case of pro-inflammatory signal-reception by DC, i.e. the reception of pathogen-
derived material or alarmins, a lot of phenotypical changes regarding cell morphology, 
sequestration of cellular material, antigen-presentation and migration take place. As 
mentioned above, at the moment of receptor-mediated activation the overall capacity for 
antigen-uptake can be strengthened. Here and during steady state a clear discrimination 
between self non-inflammatory and self or non-self inflammatory is necessary to prevent 
excess presentation of self-antigen and subsequent failures of the immune system. 
Therefore, vesicles containing PAMP as well as PRR can be differently directed and 
processed than vesicles containing self non-inflammatory molecules. This mechanism is 
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well known for TLR. Here, the sequestration and the presentation of antigen is influenced 
on many levels like vesicle acidification, motor protein phosphorylation via an p38 
scaffold,  activation  of  distinct  classes  of  proteases  and  invariant  chain  processing  as  
reviewed by JM Blander in 2007 (29). In summary, antigen degradation in phagosomes 
and formation of antigen-MHC class II molecule-complexes, which are subsequently 
presented on the cell surface via fusion of the endosome and the cell membrane, is under 
control of vesicle activation.  
The classical pathway of sequestration and presentation of exogenously acquired antigen 
as described above is supplemented by the mechanism of cross presentation. Here, 
exogenously acquired antigen finds its way into the MHC class I pathway (74) and is 
presented via MHC class I molecules on the surface of immunocompetent cells (77, 88). 
This is an important mechanism contributing to activation of specific CTL against host 
cells which are infected with viruses or intracellular parasites or bacteria. If this 
mechanism is just as well influenced by DC and/or vesicle activation like for the MHC 
class II pathway is still under investigation and debate (30). 
 
 
1.2.1.4. Properties: migration 
It is no surprise that DC migration shows comparable but counter-regulated dynamics as 
endocytosis and antigen-presentation. But, referring to the heterogeneity among DC, 
migration is not exclusively a property of activated and maturing DC (214). During steady 
state immature circulating DC permanently enter secondary lymphoid organs. In contrast, 
resident DC which show homing to peripheral tissues act as the ‘Langerhans paradigm’ 
predicts. Maturing DC start to migrate and get attracted by T cell-rich areas in secondary 
Introduction   
 
 
19 
lymphoid organs via up-regulation of chemokine receptor [CCR] 7 (56). Here, they find 
optimal circumstances for the interaction with and the activation of T cells. But first, upon 
stimulation they transiently arrest and show no migration (145, 218). This, in addition 
with the increased level of endocytosis, leads to enrichment of foreign antigen and may 
lead to full activation. 
 
 
1.2.1.5. Properties: maturation and T cell priming 
The term maturation describes the process in which DC change their morphology, regulate 
properties like antigen-uptake, -degradation and -presentation. Maturation takes place on a 
morphological as well as on a functional level. Further on, maturation is used as the term 
for the process that enables DC to activate T cells in the proper environment and therefore 
initiate protective immune responses.  
Generally, the afore mentioned properties of DC account for the prominent ability of this 
cell type to specifically tailor immune responses in presence of various pathogens under 
several conditions. But these mechanisms were more or less prearrangements. The 
property which defines DC’s ability for T cell priming is dependent on some more factors: 
First, higher levels of stable MHC class molecule-antigen-complexes (41, 92, 154, 207). 
Second, expression or up-regulation of co-stimulatory molecules which are needed for 
binding and activation of T cells (40, 94, 206). Third, cytokine expression stimulates 
proliferation and defines the route of differentiation of T cells (58, 112). These are the so-
called 3 signals that are needed to generate differentiated, antigen-specific, fully activated 
T cells.  
 
Introduction   
 
 
20 
1.2.2. T cells 
T cells develop beginning from stem cells of the bone marrow in the thymus towards 
naïve mature T cells. In contrast to DC, the term mature is used here for T cells that show 
full functionality but still are not activated. In this mature stage T cells are either CD4+ T 
helper cells or CD8+ which puts them into two distinct classes with different demands on 
activation stimuli. The fate of CD8+ T cells is to become CTL which carry out their 
effector mechanisms upon specific interaction with MHC class I molecule-antigen-
complexes. These CTL are able to selectively kill cells which show the specific antigen on 
the cell surface presented via MHC class I molecules but do not co-stimulate via CD80/86 
molecules. 
In contrast, the fate of naïve CD4+ T helper [Th0] cells is more divers. Dependent on the 
quality and on the strength of the activation event, i.e. the cell-cell contact with DC, Th0 
cells  can  develop  into  several  subclasses  with  different  obligations.  For  a  long  time  
already the concept of T cell differentiation towards Th1 and Th2 cells was known (59). 
Some more subclasses have been added since that. These subclasses need distinct 
differentiation factors and carry out different effector mechanisms ranging from acute 
inflammation [Th17] to immune silencing [Treg] which was nicely visualized on a poster 
of Chen Dong and Gustavo J. Martinez in Nature Reviews Immunology, 2010 
[http://www.nature.com/nri/posters/tcellsubsets/index.html]. 
 
 
1.2.2.1. T cell instruction 
As mentioned in 1.2.1.5 Th0 cells need at least three signals for their full activation and 
proper differentiation. These signals provide mature, activated DC: Signal 1 - antigen 
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peptide presented via MHC class II - guaranties antigen specificity of the respective T cell. 
The duration of interaction between this complex and the T cell receptor [TCR] might also 
have influence on the stability and the quality of the differentiation (90). Second, signal 2 - 
co-stimulatory molecules of the B7 family - guaranties T cell activation. Perception of 
MHC-antigen-mediated signals without the perception of co-stimulatory signals would 
lead to anergy or apoptosis of the respective T cell (11). Third, signal 3 - cytokines in the 
surrounding milieu - drives proliferation and induction of differentiation of Th0 towards 
the respective T helper cell subclass. Here, IL-2 is the prominent cytokine that induces 
proliferation whereas IL-6, transforming groth factor beta [TGF-β], IL-12, IL-10, IL-4 and 
IFNγ are the main cytokines which selectively induce differentiation (100). 
 
 
 
T cell
DC
signal 1
signal 2
signal 3
signal 3
MHC + peptide
T cell receptor
CD80/86
CD28
Cytokines
 
 
Fig. 4: Classical model of T cell instruction by activated DC. Naïve T cells need to receive 3 different 
signals to inititate differentiation, antigen-specific proliferation and activation. Interaction of the t cell 
receptor with peptide presented via MHC class molecules [signal 1], interaction of CD28 with co-
stimulatory molecules like CD80/86 [signal 2] and perception of environmental cytokines via several 
receptors determines the fate of these T cells, respectively. 
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For induction of the Th1 phenotype the cytokines IL-12 and IFNγ are greatly responsible. 
During  activation  of  Th0 cells the presence of IL-12 family members produced by 
appropriately  activated  DC and IFNγ produced  by  other  cellular  sources  [e.g.  NK cells]  
drive the expression of the transcription factor T-bet (142, 204). This leads to the 
expression  of  IFNγ by  the  respective  T  cell  and  the  differentiation  towards  the  Th1 
phenotype (102) as described in more details in the following chapter. In contrast, the Th2 
related phenotype is initiated by the presence of IL-4 produced by DC or e.g. mast cells. 
This cytokine initiates the transcription factor GATA-3 which in turn promotes IL-4 
production (142). For both processes, i.e. Th1 and  Th2 differentiation, other molecules, 
different interaction dynamics with membrane-bound ligands and receptors as well as 
timely coordination of these play a role (102). But, in this study a focus was set rather on 
the influence of the respective cytokines.  
 
 
1.2.2.2. Th1-related responses 
Before carrying out their effector functions freshly activated Th0 cells which differentiated 
towards the Th1 phenotype  in  secondary  lymphoid  organs  have  to  migrate  to  the  site  of  
microbial entry, i.e. the site of local inflammation. Therefore they express chemokine 
receptors [CXCR3 and CCR5] to migrate towards increasing levels of secreted 
chemokines which are related to local inflammation (104). Additionally, Th1 cells express 
E- and P-selectin ligands for the adhesion to vesicle walls in close distance to 
inflammatory  tissues.  After  transmigration  through the  vessel  wall  Th1 cells can directly 
interact with APC. After recognition of the cognate antigen-MHC-complex they exert 
their effector mechanism. 
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The  main  effector  mechanism  is  the  production  of  IFNγ.  This  cytokine  activates  MΦ 
which in turn are able to kill intracellular pathogens (33). These MΦ are also important in 
later steps of the immune response when clearance of cellular material after silencing of 
immune responses becomes necessary. Furthermore, phagocytosis of pathogens by MΦ is 
greatly enhanced and supported by complement binding and opsonizing antibodies. The 
production of the respective antibodies is induced and enhanced by IFNγ production and 
direct interaction between Th1 cells and B cells and therefore activation of the respective B 
cells.  Furthermore,  Th1 cells activate neutrophils by secretion of TNF and lymphotoxin 
[LT]. This leads to enhanced microbial killing at the site of inflammation. In summary, 
Th1 immune responses support cell-mediated clearance of intracellular and extracellular 
pathogens. 
 
 
1.2.2.3. Th2-related responses 
In line with 1.2.2.2 Th2 cells migrate towards increasing levels of chemokines. But, these 
chemokines are different from those which are involved in Th1 cell migration. So are the 
involved chemokine receptors - CCR3, CCR4 and CCR8 (104). Ligands for these 
chemokine receptors are typically released at sites of helminth infection. Here, Th2 cells 
release  cytokines  like  IL-4,  IL-13,  IL-5  and  IL-10.  IL-4  stimulates  activated  B  cells  to  
produce IgE that in turn can bind to helminths and consequently serves as activating 
stimulus for mast cell degranulation. In combination with IgE-binding IL-5 serves as 
activator of eosinophils which also degranulate and therefore can attack helminths (39). In 
contrast to IFNγ IL-10 suppresses MΦ activation. Globally, IL-10 can be seen as an 
immune silencing cytokine. Nevertheless, in Th2 related immune responses an alternative 
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pathway of MΦ activation can be triggered (71). In summary, the Th2 immune response is 
a mainly antibody driven response against large extracellular pathogens that is not 
effective in Leishmania infections. 
 
 
1.3. Immunobiology of leishmaniasis 
 
1.3.1. Dependency on CD4+ T cells 
Mechanisms which confer resistance to Leishmania infections are greatly dependent on T 
cell help. But, the pathway leading to protective and long lasting immunity is not quite 
straight forward. It was shown that a clonal population of preformed Th2-biased T helper 
cells respond early during infection (116). Although it was found that in some studies 
susceptible mice show stronger Th2-biased immune responses, it is under discussion if this 
is crucial for the whole process of fighting the parasite (85). Nevertheless, the conversion 
of this preformed Th2-related phenotype of the immune response towards the Th1-related 
phenotype is absolutely necessary for the healing of lesions, the clearance of parasites and 
establishment of long-lasting immunity (175). As Leishmania parasites promote their own 
unrecognized infection in neutrophils and MΦ (115), MΦ are dependent on activation 
stimuli like IFNγ. These activation stimuli are released by Th1 cells to a great extent. 
 
 
1.3.2. Dependency on CD8+ T cells 
Considering the two experimental infection modes, for high dose infection models it was 
thought that CD8+ T cells play only a role during re-infections (89, 203). This has been 
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challenged by experiments using the low dose infection model. Here CD8+ T cells were 
necessary  for  the  establishment  of  a  Th1-related immune response (22, 209). Hence, 
during beginning and ongoing Leishmania infections CD8+ T cells exert their capacity for 
parasite elimination and support the Th1 cell-driven immune response via production of 
IFNγ (83, 141). 
 
 
1.3.3. Cytokines 
A general feature of cytokines is to submit specific as well as generalized messages from 
one cell to the same [autocrine stimulation] or other cells [paracrine and endocrine 
stimulation]. IL-2 is initially released by DC and subsequently by T cells. Proliferation of 
the respective T cells is greatly dependent on this cytokine (73). IL-6 is a Janus-faced 
cytokine that serves as an inflammation marker but acts as a pro-inflammatory as well as 
an anti-inflammatory cytokine (18, 19). Cytokines which can be released by several cell 
types  are  known  to  promote  either  Th1 or  Th2 cell differentiation or activate other cell 
types. It is worth to know that Th1-  and Th2-related immune responses are not exclusive 
but inhibit each other by actions of their involved cytokines (175). In this study the 
balance between the respective cytokines was focused on to a certain extend. IL-4 and IL-
10, the major cytokines during Th2-related responses, inhibit differentiation of Th0 cells 
towards Th1 cells. Vice versa, IL-12 and IFNγ inhibit the establishment of Th2-related 
immune responses. But, one has to mention that dependent on the point of time during the 
course of T cell activation and differentiation these cytokines might play different roles. 
Therefore, experimentally acquired levels of secreted cytokines have to be interpreted 
carefully. 
Introduction   
 
 
26 
1.3.4. Additional cell types and their effector mechanisms 
Macrophages play the major role in neutralizing Leishmania parasites. Although they are 
one of the natural hosts of these pathogens, activation of MΦ by IFNγ initiates a cascade 
of effector mechanisms. Respectively, two molecules are indispensible for the effective 
clearance of Leishmania parasites during the Leishmania-specific response of the immune 
system. Nitric oxide (55, 122) and hydrogen peroxide are produced within endosomes of 
phagocytes and are potent and indispensible killers of intracellular parasites. Furthermore, 
Blos et al. demonstrated the organ-specific relevance of these two molecules (32). The 
inducible nitric oxide synthase has got a higher relevance for clearing the parasite within 
skin lesions and lymph nodes, whereas the NADPH oxidase, which converts molecular 
oxide to superoxide [O2-] is more important during the clearance of parasites in splenic 
cells. 
Neutrophils do have a dual role. Besides the production of nitric oxide that contributes to 
the clearance of parasites they are exploited as “Trojan Horses” during the initial step of 
infection (115). These cells - with a high turnover - naturally ingest parasites and digest 
them in their vacuoles until they die of apoptosis. The apoptotic cell fragments are then 
consequently ingested by macrophages. But, Leishmania parasites prolong the life-span of 
and inhibit their own destruction within their neutrophilic hosts. Additionally, it is known 
that apoptotic vesicles have immune-silencing capabilities. Therefore it is not surprising 
that these parasite-filled vesicles are taken up by MΦ with no further activation of the 
MΦ. As a consequence, the “real” hosts of Leishmania parasites are infected without them 
triggering an immune response of these cells, respectively. 
NK cells are not absolutely necessary for effective immune responses against Leishmania 
parasites (180). But, activation of NK cells by IL-12 during early phases of the infection 
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protects  BALB/c  mice  from  otherwise  lethal  infections  (121).  Naturally,  NK  cells  are  a  
source of IFNγ during infections with Leishmania in a TLR9, myeloid DC [mDC] and IL-
12 dependent manner and therefore support the formation of protective Th1 immune 
responses. More recently, it was shown that NK cells play a role in induction of protective 
immunity during vaccination with Leishmania antigen- and CpG-conditioned BMDC 
(168). 
In this model of disease NKT cells act as bystander cells which support NK cell activity. 
After systemic infection the bystander help is needed to establish NK cell cytotoxicity and 
early IFNγ production in the spleen. Whereas, overall NK cell cytotoxicity, production of 
nitric oxide and IFNγ is not impaired in mice lacking NKT cells (131). However, absence 
of NKT cells during Leishmania infections worsens the clinical outcome. 
 
 
1.3.5. Persistence of L. major in healed patients and mice 
From different clinical and experimental studies it was known that viable Leishmania 
parasites can be found in dermis and draining lymph nodes (1, 195) of healthy individuals. 
Individual amastigotes may hide in so-called ‘safe targets’: immature myeloid precursor 
cells and monocytes (136) or fibroblasts (34) as shown for L. major  For some Leishmania 
species also MΦ and hepatocytes have been determined as safe targets (49, 63, 118). But, 
if sterile cure is detrimental for the establishment of long-lasting immunity against 
Leishmania parasites or, vice versa, if containment of these parasites is necessary for 
preservation of T cell memory is under debate as reviewed by P. Scott in 2005 (184). 
There are studies emphasizing the necessity of parasite containment (21, 210) as well as a 
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study which showed long-lasting immunity against Leishmania infections in absence of 
Leishmania parasites (232). 
Nevertheless, containment of these pathogens is dependent on different molecules which 
act against these parasites. Knock-out studies revealed that depletion of inducible nitric 
oxygen species [iNOS] (195) and phagocyte NADPH oxidase [Phox] (32) leads to 
effective  emergence  of  the  parasites  and  relapse  of  disease.  More,  production  of  IL-10  
seems to play the major role for suppression of anti-Leishmanial activities in late phase of 
the immune response (176). Potent producers of this suppressive cytokine might be 
CD4+CD25+CD45RBlow T cells which can be found in BALB/c mice (157) or regulatory 
CD4+CD25+ T cells (21). 
Additionally, Leishmania parasites exhibit some mechanisms which allow immune 
evasion and might support containment in healed patients or mice. Partial resistance to 
reactive oxygen and nitrogen intermediates (68, 86, 140) as well as interference with 
antigen presentation of respective host cells (8, 43, 50, 105) and inhibition of oxidative 
burst account for these mechanisms. 
 
 
1.3.6. Interaction of DC and Leishmania parasites during the course of infection 
Due to immunoevasive mechanisms of Leishmania parasites certain kinetics of cellular 
recruitment are necessary to establish Th1 cell responses by DC (120). As Leishmania 
parasites are able to exploit specific cell types as Trojan horses (47) and thereby induce 
TGF-β expression by MΦ (76, 211) recruitment of and interaction with DC are necessary. 
With their capacity to mount strong IFNα/β-responses upon interaction with Leishmania 
parasites but without phagocytosis (179) pDC contribute to disease control (167). But, in 
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vivo studies revealed that the main effector cells for the control of leishmaniasis, i.e. 
activation of NK cell-cytotoxicity and IFNγ-production, are mDC (16, 179). 
Unfortunately, most of the studies aiming to investigate these DC-Leishmania-interactions 
did not consider the influence of sandfly bites for which it was shown that they do have 
impact on DC maturation and local inflammation (9, 48). Early Leishmania-specific 
antibody production contributes to enhanced uptake of opsonized parasites in mDC and 
LC (215, 224). As a negative result IL-10 can be found in L. amazonensis amastigote-
infected DC (162). If this displays the situation with L. major and DC is not known so far. 
Nevertheless, IL-10 in infected DC seems not to be the trigger for down-modulation of 
DC activation. It is suggested that for this immunoevasive mechanism the ongoing 
expression of 154 peptidases and additional proteinases is the key element (26, 37, 162, 
178, 225) which interfere with the JAK/STAT-, the NF-κB- and the IRF pathway. 
Furthermore, alteration of DC’s migratory capacities (13, 192) influence the antigen 
transport to draining lymph nodes by dermal DC (172). 
 
 
1.4. Immunomodulatory strategies 
 
1.4.1. Vaccination strategies 
During the last decades huge efforts have been made to develop specifically tailored 
vaccines to fight life threatening emerging diseases. But, it came out that some targets are 
not easily hit by ‘simple’ life attenuated or subunit vaccines. Therefore, the improvement 
of specific strategies was pushed forward. This includes improvements in determination of 
target epitopes of the respective pathogen (138), routes of vaccination, delivery systems to 
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specifically address APC (72), adjuvant formulations for specific instruction of effective 
immune responses (38) as well as usage of e.g. DNA (169), RNA (123), mimotopes (108) 
or peptides as carriers of information. 
 
 
1.4.2. Use of dendritic cells and derivatives for immunotherapy 
 
1.4.2.1. Dendritic cells as adjuvants for vaccination against infectious diseases and 
cancer 
DC are of central importance for linking innate and adaptive immunity and subsequently 
inducing fine-tuned immune responses due to their ability to integrate several signals. As a 
logical consequence, experimental manipulation of DC for preventive and therapeutical 
approaches was used in in vivo as well as in in vitro studies using mouse model diseases 
and cancer in human. These studies made use of either ex vivo manipulated DC and 
injection in allogeneic individuals as well as of in vivo targeting of DC with recombinant 
or cellular material. 
The  ‘ex vivo approach’ has the advantage of maturation and activation of the respective 
DC under theoretically total control. Hence, the balance between tolerance inducing and 
immunity inducing capacities could be influenced and monitored. But, due to the specific 
interaction of MHC class I and II molecules and TCR manipulated DC and the recipient 
individual have to have the same genetic background. However, a problem comes up. 
Experiments either are done in inbred strains, where one individual serves as donor of 
bone marrow and other individuals receive the expanded and differentiated cells, or e.g. in 
humans the donor and the recipient is the same individual. For studies in humans it is 
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absolutely necessary to generate these donor DC under GMP conditions and so this is a 
quite expensive effort. Consequently, studies in humans are almost exclusively done for 
therapeutical goals in cancer or AIDS.  
For the induction of protective immune responses these DC have to be properly stimulated 
and  antigen  delivery  has  to  be  adequate  for  antigen  presentation  on  MHC class  I  and  II  
molecules. There are several studies using antigen delivery via co-incubation of DC with 
the respective antigen and maturation inducing adjuvants. These DC are able to induce 
protective Th1-related immune responses after injection into syngeneic mice as shown in 
our group for the model disease leishmaniasis (61, 163, 167). Stable or transient antigen 
expression by the DC themselves is a great advantage if strong CTL responses should be 
induced by TCR stimulation via antigen-MHC class I molecule-complexes. Therefore 
transfection of DC with bacterial plasmids which harbour CpG motifs was used (107, 111) 
which was able to brake regulatory T cell induced tolerance (228). Furthermore, lentiviral 
vectors were efficiently used for such an approach in tumor models (134, 139). Another 
technique, DC-tumor cell-fusion has the great advantage that hybrid-DC are generated 
which present all relevant antigens for the induction of tumor-interfering immune 
responses (14, 109) irrespective of the use of autologous (70) or allogeneic (199) DC. 
 
 
1.4.2.2. Exosomes 
On the way towards cell-free vaccines derivatives of DC - exosomes - were used for 
vaccination studies within models of infectious diseases and cancer (213). Exosomes are 
specifically formed vesicles which differ in their protein composition from whole cell 
lysates and are enriched with several molecules which are related to immune functions 
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(45). Here, very prominent proteins are the tetraspanin family with functions related to 
cell-fusion, stimulation and motility (82). Already in 1998 these exosomes efficiently 
induced CD8+ T cell and MHC dependent growth retardation of tumors in different mouse 
models (234). Additionally, exosomes can serve as protective vaccines in infectious 
disease models as proven for Toxoplasma gondii in 2004 (4). While it was shown that 
exosomes are able to transfer MHC-peptide complexes to ex vivo generated  DC or  host  
DC and to indirectly activate T cells (10, 46, 201), Kovar et al. was able to demonstrate 
direct CD8+ T cell stimulation by exosomes in vivo (110). Hence, much potential is given 
towards exosomes-based stimulation of the immune system inducing cell-based immunity 
under controlled conditions. 
 
 
1.4.2.3. DC as targets for immunostimulatory techniques 
DC and exosome preparation ex vivo is a time and cost-expensive procedure. Hence, DC-
targeted approaches were suggested to be promising. Nicely reviewed by Proudfoot, 
Apostolopoulos and Pietersz (160), many membrane-associated molecules serve as targets 
to deliver antigen more or less specifically to DC after administration via several routes. 
For example, lectins were targeted via mannan-coated vesicles or antibodies which were 
fused to the antigen of interest. Further more, TLR, the F4/80-like receptor FIRE, Fc 
receptors, chemokine receptors and others have been addressed so far. But, this technique 
still needs lots of further studies for each of the targets as the outcome of such approaches 
is not always predictable. Instead of inducing protective immunity against a pathogen or 
cure of the respective disease a misguided immune response towards the wrong type  - 
Th1, Th2, tolerance or overshooting cytokine bursts - might be the result. 
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2. Aim of the study 
In  previous  studies  it  was  shown  that  like  for  cancer  antigen-loaded  DC  are  perfect  
vaccines or therapeutic agents. Ex vivo manipulated, they induce well controlled and 
observable immune responses. For the case of leishmaniasis it is known that antigen-
loaded DC can induce Th1-based immune responses in mice, which lead to the induction 
of IFNγ production and, as a consequence, to the destruction of Leishmania parasites 
within MΦ. But, as therapeutic vaccination against leishmaniasis is only accessable via a 
complex combination therapy (67), establishment of preventive immunity would be the 
most  reachable  goal  so  far.  To  transfer  this  to  worldwide  vaccination  of  humans  would  
have several drawbacks like DC preparation and manipulation under GMP conditions, 
individual autologous cell transfer in hospitals and 
high costs. 
 
Whereas leishmaniasis is one of the neglected diseases of which mainly poor people in 
underdeveloped countries suffer from, this type of vaccination would be affordable only 
for rich people in well developed countries. Therefore this type of vaccination has to be 
modified towards a simple and cheap formulation that brings the same properties like long 
lasting protective immunity and high reproducibility. 
It is already known that host-derived cell types have to produce IL-12 upon vaccination 
with antigen-loaded DC (163). Therefore it seems to be a feasible goal to produce a 
leishmaniasis-tailored subunit vaccine that targets the respective cell population in vivo.  
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As a consequence the following questions were addressed:  
 
Which cell population triggers the development of protective immunity after DC-based 
vaccination? 
Which type of interaction is necessary between donor DC and recipient cell types? 
What are the key factors which have to be monitored to ensure proper immune responses? 
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3.1. Device 
Device Brand
accu-jet® Brand GmbH & Co. KG, Wertheim, Germany
analytical balance Kern & Sohn GmbH, Balingen, Germany
AxioCam Carl-Zeiss AG, Oberkochen, Germany
cell culture centrifuge, Megafuge 1.0R Heraeus Sepatech GmbH, Osterode, Germany
electrophoresis power supply, EPS 500/400 Pharmacia, Piscataway, USA
electrophoresis power supply, model 200/2.0 BioRad, München, Germany
FACScalibur™ BD, Heidelberg, Germany
fluorescence microscope Carl-Zeiss AG, Oberkochen, Germany
heater Axon lab AG, Baden-Dättwil, Switzerland
incubator (for Leishmania promastigotes) WTB Binder, Tuttlingen, Germany
incubator (primary cell culture) Heraeus Instruments GmbH, Osterode, Germany
inverse microskope Carl-Zeiss AG, Oberkochen, Germany
laser scanning confocal microscope (LSM) Carl-Zeiss AG, Oberkochen, Germany
light microscope Carl-Zeiss AG, Oberkochen, Germany
magnetic stirrer Heidolph, Kehlheim, Germany
Mini Trans-Blot® BioRad, Munich, germany
Mini-PROTEAN® II BioRad, Munich, germany
Multiskan Ascent® Thermo Fisher Scientific, Waltham, USA
pH-meter Inolab/WTW, Weilheim, Germany
photometer Eppendorf, Hamburg, Germany
sterile bench Nuaire, Plymouth, MN, USA
table centrifuge, miniSpin Eppendorf, Hamburg, Germany
Thermomixer 5436 Eppendorf, Hamburg, Germany
Sonoplus HD70 Bandelin, Berlin, Germany
vortex generator Heidolph, Schwabach, Germany
water bath GFL mbH, Burgwedel, Germany  
Table 1: Alphabetic listing of technical equipment used in this study 
 
 
3.2. Reagents for cell culture and plastic material 
For the culture of primary cells and cell lines R-10 culture medium was used which 
contained RPMI 1640 [Invitrogen Karlsruhe, Germany] supplemented with 10% fetal calf 
serum [FCS, PAA Laboratories GmbH, Cölbe, Germany] 2 mM L-glutamine [Biochrom, 
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Berlin, Germany], 10 mM Hepes buffer [Biochrom], 60 μg/ml penicillin [Sigma, 
Taufkirchen, Germany], 20 μg/ml gentamycin [Sigma] and 0.05 mM 2-mercaptoethanol 
[Sigma]. For T cell proliferation assays cells were cultured in HL-1 medium [Lonza, 
Basel, Switzerland] supplemented similar to R-10 but without FCS. Sterile phosphate-
buffered saline [PBS] was from Invitrogen. The counting of viable cells was done with 
0.4% trypan Blue [Invitrogen] and the digestion of mouse tissue was performed with 
sterile Collagenase D [Roche Diagnostics, Mannheim, Germany]. Plastic 50 ml and 15 ml 
tubes were from Sarstedt [Nümbrecht, Germany]. 1.5 ml microfuge tubes were from 
Eppendorf  [Hamburg,  Gemany],  ELISA  plates  and  pipet  tips  were  from  Thermo  Fisher  
Scientific [Dreieich, Germany]. Petri dishes [60 × 15 and 90 × 16 mm] and cell scrapers 
were from BD Falcon [Heidelberg, Germany].  
Culture plates [6-, 12-, 24- and 96-well] and plastic pipets were from Greiner Bio-one 
[Frickenhausen, Germany]. 1 ml syringes were from Dispomed [Gelnhausen, Germany] 
and 2 ml and 5 ml syringes were from B. Braun Melsungen AG [Melsungen, Germany]. 
Cell strainers were purchased from BD Biosciences Pharmingen [Heidelberg, Germany]. 
 
 
3.3. Reagents and material for the treatment of mice 
Recombinant murine granulocyte-macrophage colony-stimulating factor [GM-CSF] was 
from Invitrogen [London, UK]. Recombinant human FMS-like tyrosine kinase 3 ligand 
[Flt3-L] was from CellGenix Technologie Transfer GmbH [Freiburg, Germany] E. coli-
derived LPS was from Sigma. The CpG-ODN 1668 [5´ TCCATGACGTTCCTGATGCT 
3´] were manufactured by Eurofins MWG GmbH [Ebersberg, Germany]. 
3.4. Mice 
Materials and Methods   
 
 
38 
Female BALB/c and C57BL/6 mice were purchased from Charles River Breeding 
Laboratories [Sulzfeld, Germany]. IL-12p40 and IL-12p35-deficient BALB/c mice were 
kindly provided by Dr. Gottfried Alber, University of Leipzig (130, 153) and bred in our 
institute’s animal facility. Animals were 6 to 8 weeks old at the onset of experiments and 
were kept under conventional conditions. 
For vaccination of BALB/c mice 5 × 105 viable BMDC or an equivalent amount of 
disrupted BMDC were injected i.v. into the tail vein of naive 6 - 8 week old mice. Control 
mice were treated with PBS. One week later, 2 × 105 stationary phase promastigotes were 
injected subcutaneously in the right hind footpad. The course of the infection was 
monitored weekly by measuring the increase in footpad size of the infected versus the 
non-infected footpad. 
 
 
3.5. L. major parasites and preparation of antigen lysate 
The L. major isolate MHOM/IL/81/FE/BNI used in this study has been described 
previously (190). Parasites were maintained by passage in BALB/c mice. Promastigotes 
were grown in conventional biphasic medium consisting of a solid base of rabbit-blood 
agar plus a liquid phase of R-10. Parasites used for in vivo and in vivo experiments were 
passaged 4 to 8 times in vivo to maintain maximal infectivity. For one experiment 
transgenic Leishmania promastigotes [luc2-L. major] constitutively expressing the firefly 
luciferase were kindly provided by Angela Bruder. Therefore, these Leishmania parasites 
had been stably transfected via recombination with the linearized pLEXSY-hyg2 vector 
[Jena Bioscience GmbH, Jena, Germany] where the firefly luc2 gene was introduced. In 
vivo detection of luciferase-expressing Leishmania was done via measuring the 
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luminescence emitted by parasites in the right footpad with a CCD camera 5 min. after an 
intraperitoneal [i.p.] injection of 3 mg D-Luciferin [Synchem OHG, Felsberg, Germany] 
in 200 µl per mouse together with peritoneal anaesthetic. 
For the preparation of total L. major antigen,  stationary-phase  promastigotes  were  
collected, washed three times with PBS, resuspended at 1 × 109/ml in PBS and subjected 
to six cycles of freezing and thawing at -80°C and 25°C, respectively. Leishmania antigen 
[Lmag] was stored at -80°C and aliquots were thawed not more than twice. 
 
 
3.6. Cell culture methods 
 
3.6.1. Generation of BMDC and pDC 
BMDC were generated from bone marrow progenitors according to Lutz et al. with minor 
modifications (127). Mice were sacrificed at an age of six to ten weeks. After preparation, 
femurs and tibiae were flushed with a syringe containing culture medium. Cells were 
washed and resuspended in culture medium and cell number was determined. At day of 
preparation [day zero] two million bone marrow cells were seeded into a 9 cm 
bacteriological petri dish in a volume of 10 ml R-10 medium containing 200 U/ml GM-
CSF [Pepro-Tech, London, UK]. On day three and six 5 ml of R-10 medium containing 
200 U/ml GM-CSF were added to each culture-dish. On day ten non-adherent cells were 
harvested and counted for the use in further experiments. 
Accordingly, pDC were generated from bone marrow progenitors as described by Brasel 
et al. (35) with minor modifications. Bone marrow cells were seed into cell culture flasks 
in  a  total  volume of  5  ml  with  2  ×  106 cells/ml culture medium supplemented with 200 
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ng/ml FMS-like tyrosine kinase 3 [Flt3-L, CellGenix, Freiburg, Germany]. At day eight of 
culture non-adherent cells were harvested and CD11b+ cells were depleted via magnetic 
cell sorting [MACS, Miltenyi, Bergisch Gladbach, Germany] to enrich for pDC. 
 
 
3.6.2. Antigen loading and cell disruption 
Cells were counted and one million cells per ml culture medium were seeded into petri 
dishes. Again 200 U/ml of GM-CSF were added. For antigen loading, in the presence or 
absence of 25 μg/ml CpG ODN 1668, a volume of 30µl per ml of Lmag were added, 
corresponding to 30 parasites per each cell. After 16 hours cells were harvested, washed 
three times and counted. Cell concentration was set to 5 × 106 cells per ml in ice cold PBS 
or warm R-10, depending on the further use. 
For the co-culture or the injection of viable cells, the prepared solutions were used 
directly. Instead, suspensions of non-viable BMDC [from now on called fragments] were 
obtained by incubation of the cells with 4% para-formaldehyde [PFA] for 20 min, three 
times of rapid freezing in liquid nitrogen and thawing in a water bath [37°C], or disruption 
of the cells via sonication [30 sec, cycle 70%, power MS 72/D] with an ultrasonic 
homogenizer [Sonoplus HD70]. Sonication I included one cycle of sonication for 30 sec, 
sonication II included two cycles of sonication for 30 sec. The suspensions were used 
directly or stored at -80°C before usage. 
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3.6.3. Preparation of dendritic cell fractions 
For the preparation of distinct cellular fractions of BMDC the cells were taken up in ISE 
buffer [3mM Imidazole pH 7.4, 250 mM sucrose 0.5 mM EDTA], counted and adjusted to 
5 × 106 cells per ml. After three times of rapid freezing and thawing the cellular fragments 
were homogenized by flushing the cells for 5 times with high pressure through a 5 ml 
syringe with a 26G needle. With a first centrifugation step with 3000 g for 20 minutes at 
4°C the larger cell debris could be removed. The aqueous fraction [supernatant] was taken 
to a second centrifugation step with 50,000 g [22,000 rpm, SW60 rotor] for 30 minutes at 
4°C to separate membranous particles from cytoplasmic components. For a washing step 
both  the  aqueous  fraction  and  the  pellet,  as  it  was  resuspended  in  ISE  buffer,  were  
subsequently centrifuged again with 50,000 g for 60 minutes at 4°C. From the previous 
aqueous fraction again the supernatant was taken and from the previous pellet again the 
pellet was taken and resuspended in ISE buffer. Afterwards the solutions were stored at -
80°C. 
 
 
3.6.4. Cell labelling with a fluorescent dye 
For the labelling of membranes with a red fluorescent dye PKH26 from Sigma was used. 
Cells were counted, centrifuged and resuspended in 50 µl per 1x106 cells in Diluent C. 
The same amount of Diluent C supplemented with 4 µM PKH26 was added immediately 
and incubated for 5 minutes while inverting gently. The labelling was stopped via adding 
100 µl per 1 × 106 cells  of  1%  BSA  in  PBS  and  incubating  for  one  minute.  After  the  
addition of at least 2 ml of R-10 cells were washed one time with R-10 and one time with 
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PBS. At last, cells were counted and suspended in PBS or R-10 with the required 
concentration. The whole procedure was done at 25°C. 
For the labelling of cells with a green fluorescent dye cells were labelled with CFDA from 
Invitrogen. Therefore a stock solution of 10 mM CFDA in DMSO was prepared and from 
this, a solution containing 5 µM CFDA in PBS was generated. Cells were washed and 
resuspended in PBS with a concentration of 1 × 107 cells per ml in a 15 ml Falcon tube. 
After the same amount of 5 µM CFDA in PBS was added the suspension was incubated 
for 10 minutes at room temperature [RT]. At next, the tube was filled with ice cold PBS 
and cells were washed twice with PBS at 4°C. Then, the cells were resuspended in R-10 or 
complete HL-1 medium according to the following experiment for 30 minutes. Then the 
cells were harvested, washed two times with PBS, counted and resuspended in PBS, 
complete HL-1 or R-10 with the required concentration. 
 
 
3.6.5. Co-culture Assay 
To determine the secretion of cytokines by splenocytes upon stimulation spleens of naïve 
or vaccinated mice were collected. After a digestive step of Collagenase D incubation for 
30 minutes the spleen was mashed through a 70 µm cell strainer using the plunger end of a 
5 ml syringe. Subsequently, cells were incubated in TAC buffer [0.83% NH4Cl, 0.25 mM 
Tris, pH7.2] for 5 minutes at RT to lyse red blood cells. After one washing step the cell 
suspension was adjusted to the required concentration and seeded into 48 wells. 
Subsequently the cells were stimulated with either CpG [100 µg/ml], LPS [10 µg/ml], 
Leishmania parasites [1 × 107 per ml] or a solution of BMDC fragments. after 48 hours the 
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supernatants were collected and analysed via enzyme-linked immunosorbent assay 
[ELISA] for the amount of expressed cytokines. 
 
3.6.6. Determination of cytokine release 
Supernatants generated in co-culture experiments were used to evaluate the amount of 
expressed cytokines via sandwich enzyme-linked immuno sorbent assay [ELISA]. Plates 
were coated with 50 µl of purified rat antibodies against the respective cytokine in 0.1 M 
NaHCO3, pH 8.3. The concentration of capture and detection antibodies is given in Table 
2.  
 
 
Cytokine
IFNg 0.30 µg/ml 2.00 µg/ml 25 ng/ml all BD Biosiences Pharmingen
IL-2 1.67 µg/ml 1.00 µg/ml 2.5 ng/ml all BD Biosiences Pharmingen
IL-4 2.00 µg/ml 1.00 µg/ml 2 ng/ml all BD Biosiences Pharmingen
IL-6 1.67 µg/ml 1.00 µg/ml 10 ng/ml all BD Biosiences Pharmingen
IL-10 5.00 µg/ml 1.00 µg/ml 2.5 ng/ml all BD Biosiences Pharmingen
IL-12p70 1.50 µg/ml 2.50 µg/ml 2.5 ng/ml all BD Biosiences Pharmingen
IL-12p40 3.00 µg/ml 2.50 µg/ml 10 ng/ml all BD Biosiences Pharmingen
IL-17 1.67 µg/ml 0.17 µg/ml 1 ng/ml all R&D Systems
TGFb 1.67 µg/ml 1.67 µg/ml 2.5 ng/ml all BD Biosiences Pharmingen
capture mAb 
purified
detection mAb 
biotinylated
standard max. 
conc.
 
 
 
 
After  washing  with  PBS-Tween [0.05% Tween 20,  Sigma,  in  PBS]  plates  were  blocked  
with 150 µl of blocking solution [10% FCS in PBS-Tween] for four hours at room 
temperature. Again, after washing 3 times with PBS-Tween 50µl of supernatants or one of 
eight  1:2-dilutions  of  the  respective  standards  –  with  the  maximum  concentration  as  
shown in Table 2 - were added and incubated at 4°C overnight. After three times washing 
Table 2: Concentration of antibodies used for detection of cytokines via ELISA. 
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50  µl  of  detection  antibody  was  added  at  RT  for  one  hour  and  again,  after  three  times  
washing 50 µl of streptavidin-alkaline phosphatase-complex [AKP Streptavidin, BD 
Pharmingen] was added and incubated at room temperature for one hour. At last, after 
washing three times 100 µl of 1 mg/ml p-nitrophylphosphate [phosphatase substrate, 
Sigma] in diethanolamine-buffer was added and the optical density [OD] was measured 
with a Multiskan Ascent ELISA-reader [Thermo Fisher Scientific] at a wavelength of 405 
nm and a reference wavelength of 490 nm. 
The concentrations of cytokines were calculated with the Ascent Software via 
extrapolating  the  OD  values  of  the  samples  to  the  multiparametric  regression  of  the  
standard curve. Cytokine detection thresholds were 200 pg/ml for IFNγ, 20 pg/mL for IL-
2,  16 pg/mL for IL-4, 80 pg/mL for IL-6, 20 pg/mL for IL-10, 80 pg/mL for IL12-p40, 20 
pg/mL for IL12-p70, 8 pg/mL for IL-17 and 20 pg/mL for TGFβ. 
 
 
3.6.7. Proliferation assay 
To  determine  the  capability  of  BMDC  fragments  to  induce  T  cell  proliferation  a  
suspension of three different cell populations was set up. The population containing the 
Leishmania antigen specific T cells was obtained from mice which were vaccinated with 
sonicated, Lmag-loaded and CpG-activated BMDC [BMDC L/C, son.] and infected with 2 
× 105 L. major parasites into the right footpad one week later. One week post infection 
spleens were collected, digested and single cell suspension was prepared. As a source for 
DC, spleens of naïve mice were collected. After preparation of single cell suspension DC 
were enriched via MACS using CD11c [N418] MicroBeads [Miltenyi] according to 
manufacturer’s guidelines. The third population consisted of a suspension of sonicated 
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Lmag-loaded, CpG-activated BMDC. All viable cells were labelled with CFSE as 
described in 3.6.4. All cells were resuspended in HL-1 medium and co-cultured at a ratio 
of 2 × 106 splenocytes  to  2  ×  105 DC  to  2  ×  105 BMDC.  After  3  to  5  days  the  cell  
suspensions were centrifuged, supernatants were collected and stored at -20°C for 
cytokine analysis. After a washing step with PBS the cells were labelled with antibodies 
against CD4 and CD8 [BD Pharmingen]. Via FACS analysis the CFSE-dilution of CD4+ 
and CD8+ cells was measured. 
 
 
3.6.8. Mouse perfusion and cryosectioning of spleens 
For the tracking of i.v.-injected DC, 5 × 105 CFSE-labelled BMDC were injected into the 
left  tail  vein.  Three  hours  later  mice  were  anesthetized  with  a  lethal  dose  of  up  to  2  mg 
Ketanest S [Pfizer Pharma GmbH, Berlin, Germany] and 0.2 mg Rompun [Bayer Animal 
Health GmbH, Leverkusen, Germany] per mouse. Then the mice were fixed and the breast 
was opened so that the left ventricle could be penetrated. After a few seconds of PBS 
pumping  the  vein  on  the  right  side  of  the  heart  was  cut  to  let  the  blood  flow  out.  PBS  
pumping was followed until the efflux was cleared of blood. Then PBS was replaced with 
a solution of 4% PFA in 0.1 M sodium phosphate buffer with a pH of 7.2 and the mouse 
was perfused for 25 minutes. After this, the spleen was collected from the mouse and was 
post-fixed with the same solution for 24 h. Before the spleen was frozen, it had been cryo-
protected via incubation in 20% sucrose solution for about 48 h. Afterwards the spleen 
sample was arranged in plastic Cryomolds and embedded in Tissue Tek O.C.T. [both 
Sakura Finetek Europe B.V., Zoeterwoude, Netherlands] and frozen in a cup that had been 
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filled with isopentane and cooled by a bath of liquid nitrogen. For short time storage the 
samples were then kept at -80°C. 
Spleen samples were then cut into 10 - 20 µm thick sections using Microm blades 
[Thermo  Fisher  Scientific]  in  a  microtome  cryostat  HM  500  CM  [Microm  International  
GmbH, Walldorf, Germany] and placed onto SuperFrost Plus glas slides [Menzel GmbH 
& Co KG, Braunschweig, Germany]. 
 
 
3.6.9. Immunofluorescence staining 
For immunofluorescence staining of spleen sections samples were treated as follows: Prior 
to staining glas slides were incubated in acetone at -20°C for 10 minutes. For some 
antibodies, as shown in  
Table 3, some slides were blocked with antibodies against Fc receptors [CD16/32] in a 
solution consisting of 20% rat serum in PBS-Tween. Afterwards slides were incubated 
with the respective antibodies. After the staining procedure glas slides were prepared for 
microscopical analysis via the LSM. 
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3.6.10. Limiting dilution assay 
The number of infected cells in the lymph nodes draining the infected footpads was 
determined by limiting dilution analysis (202). Six to seven weeks post infection, mice 
were sacrificed and single cell suspensions were obtained from pooled draining lymph 
nodes. Serial dilutions ranging from 2 × 106 to 1.2 × 102 cells per ml [protected mice] or 2 
× 105 to 12 cells per ml [susceptible mice] were seeded into microculture plates [100 
µl/well] containing 50 µl of a blood-agar slant to support the growth of parasites. For each 
dilution, 16 replicates were set up and incubated for 10 days at 28°C and 5% CO2 in a 
humidified atmosphere. Leishmania-negative wells were identyfied using an inverted 
microscope and the estimation of infected cells in the draining lymph nodes was 
calculated. 
 
 
 
antibody source isotype incubation conc. of antibody
mabαCD4-
PE rat IgG2a
10min 
acetone
30min 
mabαCD16/32 in 
20% rat serum
30min in 
20% rat 
serum
1µg/ml
mabαCD11c-
PE
armenian 
hamster IgG1
10min 
acetone w/o
60min in 
5%FCS 1µg/ml
mabαCD45R-
PE rat IgG2a
10min 
acetone
30min 
mabαCD16/32 in 
20% rat serum
30min in 
20% rat 
serum
0.2µg/ml
prestaining procedure
 
 
Table 3: Staining procedure of cryo-sections of spleen samples for different markers. Sections were 
pre-treated as indicated. Briefly, sections were post-fixed with acetone and blocked with monoclonal 
antibody against [mabα] CD16/32 in the respective serum. The same serum was used to incubate with 
the staining antibody with the indicated concentrations, PE: phycoerythrin. 
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3.6.11. Analysis of cytokine production of lymph node cells and splenocytes 
To elucidate the cytokine expression of lymph node cells and splenocytes in the course of 
disease lymph nodes and spleens were harvested from sacrificed mice 6 – 7 weeks post 
infection. After preparing a single cell suspension as mentioned above splenocytes were 
incubated  for  5  minutes  in  TAC  buffer  at  RT  and  both  cell  suspensions  were  washed  
subsequently, resuspended in R-10, counted and adjusted to 1 × 106 cells per ml. Per 
vaccination group and treatment – re-stimulation with 10 µl L.major lysate or 10 µl PBS - 
1 ml of each cell suspension was seeded in 48wells as duplicates. 48 hours later 
supernatants were collected and the amount of produced cytokine was measured via 
ELISA. 
 
 
3.6.12. Statistical analysis.  
Results  of  all  experiments  were  analyzed  using  the  GraphPad  Prism  4.03  software.  For  
determining statistical significance of the vaccination experiments and each of the co-
culture experiments, multiple group comparisons were performed by one-way ANOVA 
with  Dunnett’s  post  test  to  compare  all  samples  against  the  control  sample.  For  
comparison of all co-culture experiments a two-way ANOVA was performed. 
Additionally Bonferroni’s post test was used to compare all groups. To determine the 
statistical significance between two distinct samples, the two-tailed unpaired t-test was 
used. 
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4. Results 
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4.1. In vitro generation of pDC 
 
4.1.1. Growth kinetics 
Ambitious scientific approaches regarding pDC-based vaccination against Leishmania 
parasites are exacerbated due to the large numbers of mice needed to isolate appropriate 
amounts of pDC as pDC are low in cell numbers and not easy to handle during the process 
of preparation, antigen-loading and re-injection into the recipient mice. Therefore we 
started to raise pDC in vivo. For this purpose, we cultivated bone marrow stem cells in the 
presence of the growth factor Flt3-L for eight days. Fig. 5A shows the growth kinetics of 
bone marrow stem cells cultured in Flt3-L-containing medium. Cells were harvested at 
day eight for further use in experiments. Therefore CD11b+ cells, i.e. conventional or 
myeloid dendritic cells, were depleted via MACS. Fig. 5B shows an average rate of yield 
between three to four million pDC per culture flask. 
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Fig. 5: Analysis of cells derived from bone marrow and grown in culture medium supplemented with 
Flt3-L. A: Growth kinetics of total cells per 5 ml culture medium supplemented with 200 ng/ml Flt3-L. B: 
Representative yield of bone marrow cells after eight days of culture in Flt3-L-containing medium before 
and after MACS for CD11b. mDCs: conventional myeloid dendritic cells; pDCs: plasmacytoid dendritic 
cells. 
Results   
 
 
51 
The high yield of pDC generated from precursor cells in vitro emerged to be an attractive 
method to be used in our model of pDC-based vaccination. From this moment on 
sufficient numbers of cells were available to conduct substantial studies in this field. 
 
 
4.1.2. In vitro grown pDC do not need pre-activation via CpG ODN 
It was established in our laboratory that Leishmania lysate  serves  as  a  sufficient  whole-
parasite antigen for the presentation of relevant epitopes to induce protective immune 
responses. But likewise, the low stimulatory activity of Leishmania lysate in terms of DC 
activation is known. Using different DC subsets for our DC-based vaccination strategy 
revealed that ex vivo antigen-loaded pDC do not need additional activation via CpG ODN 
to serve as a potential vaccine carrier against infections with L. major (167).  
To evidence, whether this holds true for in vitro-cultured pDC, we injected antigen-loaded 
pDC i.v., co-incubated with lysate either in the presence or absence of CpG ODN. Control 
mice were treated with PBS or naïve pDC. 
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Fig. 6 clearly demonstrates the successful immunization, comparable to ex vivo-prepared 
pDC (167), using in vitro-grown pDC as vaccine carrier, independent of additional 
activation  with  CpG ODN,.  In  contrast  to  both  control  groups,  mice  of  both  groups  that  
were vaccinated with antigen-loaded pDC perform equally in terms of controlled footpad 
swelling and reduced parasite load in draining lymph nodes. Differences were only seen 
for cytokine production upon re-stimulation with L.m. lysate  of  splenocytes  and  lymph  
node cells six weeks post infection (Fig. 7). 
Fig. 6: Monitoring of disease parameters after vaccination and subsequent infection with L. major. 
pDC were pretreated as indicated A: Development of footpad swelling after infection with L. major into the 
right footpad of vaccinated mice. ANOVA p value < 0.0001; Dunnett’s post test: **, p ≤ 0.01. B: 
Determination of parasite load in pooled draining lymph nodes of the respective vaccination groups six 
weeks post infection. pDC lysate: Leishmania lysate-loaded pDC; pDC lysate+CpG: Leishmania lysate-
loaded and CpG-activated pDC. The data shown is representative for three independent experiments with at 
least 4 mice per group. 
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Fig. 7: Cytokine profiles of spleen and LN cells after challenge with L. major antigen. Six  weeks  post 
infection splenocytes and dLN cells of vaccinated mice were re-stimulated with Leishmania lysate. 
Supernatants were collected and cytokine levels of IL-4 [A], IL-6 [B], IL-10 [C] and IFNγ [D] were 
determined via ELISA. unstim.: without stimulation, open bars; lysate: re-stimulation with Leishmania lysate, 
black bars; pDC lysate: Leishmania lysate-loaded pDC; pDC lysate+CpG: Leishmania lysate-loaded and 
CpG-activated pDC. The data are representative of three independent experiments. 
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Here, the strong immune-stimulatory capacity of antigen-loaded pDC was indicated by 
elevated  levels  of  IL-6,  IFNγ and  IL-10,  whereas  these  cytokines  were  differentially  
expressed by these two groups. Vaccination with antigen-loaded and CpG-activated pDC 
results in high levels of IL-6, IL-10 and IFNγ within the spleen but not within the lymph 
node. Compared to this, antigen-loaded pDC caused high levels of IL-6- and IFNγ  by 
lymph node cells. These differences become more evident by calculating the ratio of 
expressed IFNγ vs. IL-10 [Fig. 8]. 
 
 
 
 
 
4.2. Antigen presentation in the spleen after i.v. injection of antigen-loaded 
BMDC 
Commonly, DC are well known for their ability to catch antigens, to present the relevant 
epitopes via MHC molecules and to mediate coordinated immune responses. These 
Fig. 8: Ratio of IFNγ to IL-10 in the supernatants of spleen and LN cells 6 wk after footpad infection with 
L. major. Ratios of IFNγ to IL-10 in the supernatants were calculated from the cytokine levels detected by 
ELISA  for   spleens  [A] and lymph nodes [B]. Where no cytokine was detected, the value of the detection 
threshold of the ELISA was used for calculating the ratio. pDC lysate: Leishmania lysate-loaded pDC; pDC 
lysate/CpG: Leishmania lysate-loaded and CpG-activated pDC The data are representative of three 
independent experiments. 
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abilities are taken in advantage when injecting DC-based vaccines into animals and men. 
To gain closer insights into the mode of action of our well established DC-based 
vaccination with viable antigen-loaded BMDC against L. major, we started to monitor the 
fate of i.v. injected BMDC after administration. For that reason 5 × 105 CFSE-labelled 
BMDC were injected into the tail vein.  
 
 
 
 
At different time points, mice were PFA-perfused and cryo-section of spleens were 
prepared to localize these CFSE-labelled BMDC in the spleen. Surprisingly, already three 
hours post administration the BMDC did not appear as intact cells, but small CFSE-
labelled particles were detected in the spleen, unlike our expectations. This unexpected 
finding gave rise to the question whether protective T cell immunity is initiated before 
fragmentation of antigen-loaded BMDC or whether fragments of antigen-loaded DC on 
 
 
Fig. 9: Immunohistochemistry of spleen sections. The picture shows a green fluorescent particle in contact 
with a CD4+ [red] T cell. 5 × 105 CFSE-labeled antigen-loaded BMDC were injected i.v. into the tail vein of 
a BALB/c mouse. 3 hours later the spleen was harvested after mouse-perfusion and cryo-sections of the 
spleens were prepared. The picture is representative for three independent experiments. 
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their own, posses the ability to serve as potential adjuvant for sufficient antigen-
presentation. 20 – 25% of all CFSE-labelled particles were taken up by cells which 
directly interact with CD4+ T cells, but only 3.5 – 4.5% interact with CD45R+ B cells. 
This correlates with the fact that for efficient vaccination against Leishmania parasites and 
the efficient destruction of replication sites a cell-based immune response is necessary. 
 
 
4.3. Minimal requirements for BMDC-based vaccination 
 
4.3.1. Viability and integrity of dendritic cells as a cell-based vaccine is not an 
prerequisite to mediate immunity 
It was believed that DC-based vaccination is dependent on active and direct antigen-
specific interaction between the vaccinating DC and T cells in secondary lymphoid organs 
(61, 197). The results of 4.2 together with preliminary tests using PFA-fixed or UV-
irradiated antigen-loaded CpG-activated BMDC showed that viability of BMDC is not 
required for the efficiency of cell-based vaccination strategies (181). To test whether the 
initiation of a protective T cell immunity in vivo depends on intact cell membranes of the 
vaccine carrier, we disrupted antigen-loaded CpG-activated BMDC prior to administration 
to BALB/c mice. These BMDC were either disrupted via rapid freezing and thawing or 
via sonication. This leads to fragments of BMDC ranging from the size of large cell ghosts 
to small fragments which are hardly visible with conventional light microscopy. 
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BMDC-vaccinated mice were protected against a subsequent infection with L. major 
promastigotes in terms of reduced footpad swelling compared to the PBS treated mice. In 
addition, a limiting dilution assay of draining lymph nodes revealed reduced numbers of 
Leishmania-infected cells. This demonstrates that effective vaccination against 
experimental leishmaniasis is independent of the size of disrupted BMDC. 
 
 
4.3.2. Pre-activation of BMDC prior to vaccination is not necesarry 
The results of 4.2 and 4.3.1 suggest a possible indirect mechanism of T cell-activation by 
vaccination with antigen-loaded CpG-activated DC. I.e., antigen-loaded CpG-activated 
DC  do  not  interact  directly  with  T  cells  but  might  serve  as  antigen-carrier  with  
immunogenic activity. Nonetheless, host DC might be the major player in this setting. But, 
presentation of co-stimulatory molecules by the immunogenic cell or compound, like 
Fig. 10: Monitoring of disease parameters after vaccination and subsequent infection with L. major.  
A: Development of footpad swelling after infection with L. major into the right footpad of mice which have 
been vaccinated as indicated. ANOVA p value = 0.0002; Dunnett’s post test: **, p ≤ 0.01. B: Determination 
of parasite load in pooled draining lymph nodes of the respective vaccination groups six [five for PBS] 
weeks post infection. BMDC L+C: Leishmania lysate-loaded CpG-activated BMDC; f’nth: freeze and thaw; 
son. I: one cycle of sonication; son. II: two cycles of sonication. The data shown are representative for three 
independent experiments with at least 4 mice per group. 
0
0.5
1
PBS BMDC
L/C,
f'nth
BMDC
L/C,
son. I
BMDC
L/C,
son. II
pa
ra
si
te
lo
ad
in
 
dr
ai
ni
ng
ly
m
ph
 n
od
es B
0
1
2
3
4
5
1 2 3 4 5 6
weeks after infection
fo
ot
pa
d
sw
el
lin
g
(m
m
) PBS control
BMDC L+C, f‘nth
BMDC L+C, son. I
BMDC L+C, son. II
A
Results   
 
 
58 
expression of e.g. CD80 and CD86, prior to disruption of transferred DC might play a 
minor role for proper activation of host DC. To test whether pre-activation of BMDC is 
still necessary in this setting of BMDC fragments-based vaccination mice were vaccinated 
with fragments either derived from antigen-loaded BMDC, prepared in the presence or 
absence of CpG or PBS as control. The results clearly demonstrate that activation of 
antigen-loaded BMDC prior to cell-disruption is not a prerequisite for vaccine efficiency 
[Fig. 11]. Mice vaccinated with sonicated antigen-loaded BMDC performed at least equal 
to mice which were vaccinated with pre-activated antigen-loaded BMDC in terms of 
footpad swelling and parasite load in the draining lymph nodes seven weeks post infection 
with L. major. 
 
 
 
 
 
 
Fig. 11: Monitoring of disease parameters after vaccination and subsequent infection with L. major. 
A: Development of footpad swelling after infection with L. major into the right footpad of mice which have 
been vaccinated as indicated. ANOVA p value < 0.0001; Dunnett’s post test: **, p ≤ 0.01. B: Determination 
of parasite load in pooled draining lymph nodes of the respective vaccination groups seven weeks post 
infection. BMDC L+C, son.: sonicated Leishmania lysate-loaded CpG-activated BMDC; BMDC lysate, son.: 
sonicated Leishmania lysate-loaded BMDC. The data shown are representative for three independent 
experiments with at least 4 mice per group. 
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4.3.3. Disrupted antigen-loaded pDC can serve as a vaccine carrier 
Obviously, we were interested in assessing a common ability of disrupted antigen-loaded 
BMDC and pDC, as disrupted antigen-loaded BMDC showed good efficiency in 
mediating protective immunity,. To investigate DC-based vaccination strategies further, it 
was necessary to discover if vaccination with disrupted cells is unique for antigen-loaded 
BMDC. Therefore, mice were vaccinated either with sonicated antigen-loaded pDC and 
pure pDC or PBS as controls. In comparison to the results shown in 4.3.2 sonicated 
antigen-loaded pDC show the same ability of providing immunity in the same way as 
sonicated antigen-loaded BMDC. 
 
 
 
 
 
A tendency of progressive footpad swelling of mice upon immunization with naïve pDC 
in comparison to PBS-treated mice was observed in these and other experiments. This 
Fig. 12: Monitoring of disease parameters after vaccination and subsequent infection with L. major. 
A: Development of footpad swelling after infection with L. major into the right footpad of mice which have 
been vaccinated as indicated. ANOVA p value = 0.0002; Dunnett’s post test: **, p ≤ 0.01. B: Determination 
of parasite load in pooled draining lymph nodes of the respective vaccination groups seven weeks post 
infection. pDC son.: sonicated pDC; pDC lysate, son.: sonicated Leishmania lysate-loaded pDC. The data 
shown are representative for two independent experiments with at least 4 mice per group. 
 
PBS pDC
sonicated
pDC
lysate, son.
0
0.01
0.02
0.2
0.6
1.0
pa
ra
si
te
lo
ad
in
 
dr
ai
ni
ng
ly
m
ph
 n
od
es B
0
1
2
3
4
5
6
1 2 3 4 5 6 7
weeks post infection
fo
ot
pa
d
sw
el
lin
g
(m
m
) PBS
pDC, son.
pDC lysate, son.
A
Results   
 
 
60 
might be associated with a misled immune response as an reaction to a stimulus without 
foreign peptides. In contrast, the decrease of footpad swelling in the PBS control group 
during the last week of experiment seems to be related to dissemination of parasites as 
these mice appeared to be sick and less vital as the other mice. This is backed up by the 
very low number of infected cells in draining lymph nodes of clinically protected mice. 
According to Fig. 7a similar cytokine pattern was observed after re-stimulation of 
splenocytes and lymph node cells seven weeks post infection [Fig. 13]. 
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Fig. 13: Cytokine profiles of spleen and LN cells after challenge infection with L. major. Seven weeks 
post infection splenocytes and dLN cells of vaccinated mice were re-stimulated with Leishmania lysate. 
Supernatants were collected and cytokine levels of IL-4 [A], IL-6 [B], IL-10 [C] and IFNγ [D] were 
determined via ELISA. unstim.: without stimulation, open bars; lysate: re-stimulation with Leishmania lysate, 
black bars. pDC son.: sonicated pDC; pDC lysate, son.: sonicated Leishmania lysate-loaded pDC. The data are 
representative of two independent experiments. 
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Again, ratios of IFNγ vs. IL-10 were calculated to emphasise the difference between 
protected and non-protected vaccination groups.  
 
 
 
 
 
4.3.4. The protective effect of disrupted cell-based vaccination is independent of 
the type of APC and the H-2 haplotype 
It became clear that neither cell viability or cell integrity [4.3.1] nor types of DC [4.3.3] 
were important for the protective effect of DC-based vaccination against L.major In 
consequence, the question arose which mechanisms cause the success of disrupted DC-
based vaccination. To answer this question, we examined the necessity of appropriate 
antigen presentation via syngenic MHC molecules to provide protection in BALB/c mice. 
Accordingly, solutions of sonicated antigen-loaded cells derived from in vitro grown bone 
marrow-derived BALB/c MΦ and a BALB/c derived MΦ cell line [J-774A.1] were tested 
in vaccination experiments. MΦ do have the ability of antigen uptake, processing and 
Fig. 14: Ratio of IFNγ to IL-10 in the supernatants of spleen and LN cells 6 wk after footpad infection 
with L. major. Ratios of IFNγ to IL-10 in the supernatants were calculated from the cytokine levels detected by 
ELISA  for   spleens  [A] and lymph nodes [B]. Where no cytokine was detected, the value of the detection 
threshold of the ELISA was used for calculating the ratio. pDC son.: sonicated pDC; pDC lysate, son.: 
sonicated Leishmania lysate-loaded pDC. The data are representative of two independent experiments. 
10
20
30
40
50
60
70
PBS pDC, son. pDC
lysate, son.
R
at
io
 IF
N
γ
: I
L-
10
B lymph node
0
unstim.
lysate
0
60
120
180
PBS
pDC, son. pDC
lysate, son.
unstim.
lysate
R
at
io
 IF
N
γ
: I
L-
10
A spleen
Results   
 
 
63 
presentation but lack some DC-specific features. Additionally, sonicated antigen-loaded 
C57BL/6 BMDC [H-2kb] were tested in this experiment as they exhibit a different MHC 
haplotype in comparison to BALB/c mice [H-2kd]. 
The vaccination experiment revealed that antigen-loaded CpG-activated MΦ and C57BL/6 
BMDC have the ability to provide protective immunity against L. major infections in 
BALB/c mice with regard to controled footpad swelling and reduced parasite load in the 
draining lymph nodes [Fig. 15]. Therefore, neither a DC-specific ability nor antigen-
presentation via MHC class molecules by the donor DC are necessary for the induction of 
protective immunity against a subsequent infection with Leishmania major in the recipient 
mice. 
 
 
 
 
 
Fig. 15: Monitoring of disease parameters after vaccination and subsequent infection with L. major.  
A: Development of footpad swelling after infection with L. major into the right footpad of mice which have 
been vaccinated as indicated. ANOVA p value = 0.0063; Dunnett’s post test: *, p ≤ 0.05; **, p ≤ 0.01. B: 
Determination of parasite load in pooled draining lymph nodes of the respective vaccination groups seven 
weeks post infection. BMDC L+C, son.: sonicated Leishmania lysate-loaded CpG-activated BMDC; BL6 
BMDC: BMDC derived from C57BL6 mice; prim MΦ: BALB/c bone marrow-derived MΦ. The data shown 
are from a single experiment with five mice per vaccination group. 
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The elevated footpad swelling of the MΦ cell  line-vaccine together with a tendency to a 
higher level of parasitized cells in draining lymph nodes might be due to normal variation 
during experiments. Beyond this, all mice which received disrupted antigen-loaded cells 
performed almost equally in terms of footpad swelling and parasite load in draining lymph 
nodes. 
Looking at cytokines released by splenocytes or cells of lymph nodes, it becomes clear 
that after six weeks post infection LN are of more importance than the spleen. Only in 
lymph nodes IFNγ was expressed to a higher extend by cells of protected mice than by 
cells of PBS control-treated mice. Again, looking for the IFNγ : IL-10 ratio the difference 
between spleen and LN becomes apparent. Further more, no difference was seen between 
the cytokine patttern of BALB/c or BL6 DC. 
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Fig. 16: Cytokine profiles of spleen and LN cells after challenge infection with L. major. Seven weeks post 
infection splenocytes and dLN cells of vaccinated mice were re-stimulated with Leishmania lysate. Supernatants 
were collected and cytokine levels of IL-4 [A], IL-6 [B], IL-10 [C] and IFNγ [D] were determined via ELISA. 
unstim.: without stimulation, open bars; lysate: re-stimulation with Leishmania lysate, black bars; n.d.: not 
detected. The data shown are from a single experiment with five mice per vaccination group. 
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4.4. In vitro studies of the stimulatory effect of DC fragments on murine 
splenocytes 
 
4.4.1. Fragments of antigen-loaded DC induce antigen-specific T cell proliferation 
While it has been described that viable antigen-loaded DC trigger the activation, 
maturation and proliferation of naïve and primed T cells, the effect of disrupted antigen-
loaded DC used as vaccine against Leishmania parasites on T cells was not known so far. 
The above shown results demonstrate the terminal outcome of disrupted cell-based 
vaccination against L. major infections. Reduced footpad swelling and reduced parasite 
load in draining lymph nodes has been demonstrated several times. But, early events 
during activation of protection-transferring immune responses have not been elucidated so 
far. Consequently, we started to investigate the capacity of sonicated antigen-loaded CpG-
activated BMDC to activate T cells in in vitro co-cultures of disrupted DC together with 
Fig. 17: Ratio of IFNγ to IL-10 in the supernatants of spleen and LN cells 7 wk after footpad infection with  
L. major. Ratios of IFNγ to IL-10 in the supernatants were calculated from the cytokine levels detected by 
ELISA for  spleens  [A] and lymph nodes [B]. Where no cytokine was detected, the value of the detection 
threshold of the ELISA was used for calculating the ratio. 
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the respective cell populations. However, neither co-cultures of CD4+ T cells nor co-
cultures of CD8+ T cells together with fragments of antigen-loaded BMDC showed any T 
cell  proliferation  in  comparison  to  controls  [data  not  shown],  even  if  the  T  cells  were  
isolated from primed mice. Additionally, co-cultures of splenic DC from naïve mice 
together with T cells and the respective solutions of sonicated antigen-loaded BMDC were 
ineffective in inducing T cell proliferation [data not shown]. Effective CD4+ and CD8+ T 
cell proliferation only took part in co-cultures of complete splenocytes of primed mice 
together with splenic DC of naïve mice which were stimulated with fragments derived 
from antigen-loaded CpG-activated BMDC or viable antigen-loaded BMDC as control 
[Fig. 18]. 
 
 
Fig. 18: CFSE-proliferation assay of splenocytes stimulated with antigen-loaded BMDC. Antigen-
specific T cell proliferation upon stimulation with disrupted antigen-loaded BMDC. Therefore splenocytes of 
primed mice, splenic DC of naïve mice and BMDC, treated as indicated, were CFSE-stained and cultured 
together for five days. After staining for CD4 [A] or CD8 [B] using PE-labelled antibodies CFSE-dilution 
was determined via FACS analysis. The data are representative of three independent experiments. Cells were 
prepared in each case from two identically pre-treated mice. The data shown are representative of three 
independent experiments 
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Despite the antigen-unspecific T cell proliferation observed in co-cultures where no 
Leishmania antigen has been introduced [right columns, Fig. 18], marked antigen-specific 
T cell proliferation could be observed for splenocyte co-cultures which were stimulated 
with either viable or disrupted antigen-loaded CpG-activated BMDC. Both populations of 
T cells, i.e. CD4+ and CD8+ T cells show high proliferation rates on day 5. This clearly 
demonstrates that signal 1 and signal 2 which are needed for sufficient T cell activation 
and proliferation are provided in this setting of lymphocyte co-cultures. 
 
 
 
 
Fig. 19: Cytokine release of splenocytes during antigen-specific T cell proliferation. According to Fig. 
18, splenocytes and BMDC were CFSE-labelled and co-cultured. After four and five days supernatants were 
taken for subsequent Cytokine analysis via ELISA. Data are representative for three independent 
experiments. Cells were prepared in each case from two identically pre-treated mice. 
12
16
IF
N
γ
in
 n
g/
m
l
0
4
8
0
1
2
3
4
IL
-6
 in
 n
g/
m
l
0
0.05
0.1
0.15
0.2
0.25
BMDC
L+C
BMDC
L+C,
son.
w/o
IL
-2
 in
 n
g/
m
l
IL
-4
 in
 n
g/
m
l
0
0.5
1
1.5
2
IL
-1
0 
in
 n
g/
m
l
d4
d5
IL
-1
2 
in
 n
g/
m
l
BMDC
CpG,
son.
BMDC
L+C
BMDC
L+C,
son.
w/oBMDC
CpG,
son.
BMDC
L+C
BMDC
L+C,
son.
w/oBMDC
CpG,
son.
BMDC
L+C
BMDC
L+C,
son.
w/oBMDC
CpG,
son.
d4
d5
d4
d5
0
0.25
0.5
0.75
1
0
0.5
1
1.5
2
BMDC
L+C
BMDC
L+C,
son.
w/oBMDC
CpG,
son.
BMDC
L+C
BMDC
L+C,
son.
w/oBMDC
CpG,
son.
d4
d5
d4
d5
d4
d5
Results   
 
 
69 
Although, the specific clearance of pathogens depends on both, the activation of T cells 
via signal one and two and directing T helper cell fate which are necessary during initial 
and continuous T helper cell priming. Therefore, the release of cytokines which are related 
to a Th1-related or Th2-related immune response was monitored. Accordingly, we 
determined the amount of IL-2, IL-4, IL-6, IL-10, IL-12p70 and IFNγ for 5 days, 
beginning at day 1 after co-incubation [data shown for days 4 and 5]. In Fig. 19 it is 
shown that a high amount of IFNγ is produced upon stimulation with antigen-loaded 
BMDC - either viable or disrupted - but not by splenocytes which were stimulated in the 
absence of Leishmania antigen. IL-2 was produced concomitantly or rather initially to the 
T cell proliferation on days 1 to 3. Because of that reason, already decreasing levels of IL-
2 have been detectable on day 4 and 5. Antigen-specific production of IL-4 and IL-10 
which act as counterparts to the Th1-related cytokines was also observed. At last, IL-6, a 
marker for inflammatory immune responses was also up-regulated upon stimulation with 
BMDC. A control sample containing splenocytes of primed mice and fragments of 
antigen-loaded CpG-activated BMDC but no splenic DC of naïve mice did not show 
antigen-specific proliferation but the same amount of IL-4 compared to the equivalent 
sample  with  naïve  splenic  DC.  These  results  showed that  IL-4  production  in  this  setting  
might be rather a side effect of splenocyte stimulation than a specific signal 3 to T cells. 
 
 
4.4.2. Fragments of antigen-loaded BMDC induce Th1-biased cytokine production 
The importance of a cytokine shift from a Th2-biased  towards  a  Th1-biased immune 
response in non-self-healing leishmaniasis is well known (66, 125). Additionally, it is 
known that BALB/c mice tend to promote a Th2-related immune response that can be 
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reverted via DC-based vaccination towards a self-healing state of immunity. For the use of 
disrupted BMDC so far it  was not known in which way the type of immune response is 
modulated. As the spleen is mainly targeted via the i.v. injection route we started 
extensive in vitro studies as a first step to determine the impact of fragments derived from 
antigen-loaded BMDC on the cytokine release of splenocytes of naïve mice. For that 
reason we stimulated splenocytes of naïve mice either with PBS, LPS or CpG as controls 
or with disrupted antigen-loaded BMDC to simulate the act of vaccination. 
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The results in Fig. 20 show enhanced production of IL-2 and IL-12p40/p70 upon 
stimulation of naïve splenocytes with disrupted BMDC. IL-4 was never detected in the 
Fig. 20: Cytokine production of naïve splenocytes after stimulation with disrupted BMDC. Single-cell 
suspensions of spleens were prepared from naïve BALB/c mice. Cells were cultured for 48 hours with the 
respective stimuli. Afterwards supernatants were collected and cytokine levels were determined via ELISA. 
ANOVA p values: p < 0.0001 for IFNγ; p = 0.0088 for IL-2; p < 0.0001 for IL-6; p < 0.0001 for IL-12p40; 
p < 0.0001 for IL-12p70. Dunnett’s post test: *, p <  0.05.  Data  represent  the  mean  ±  SD  of  at  least  four  
independent experiments. BMDC L+C, son.: sonicated Leishmania lysate-loaded CpG-activated BMDC; 
n.t.: not tested. 
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samples with disrupted BMDC [data not shown]. Therefore a Th1-favoring and T cell 
proliferation-initialising cytokine milieu was found in these culture samples.  
Many in vitro assays showed that Leishmania lysate has some suppressive impact on the 
cytokine production of lymphocytes [data not shown]. Hence, slight differences in 
cytokine production between naïve splenocytes upon stimulation with either disrupted 
antigen-loaded BMDC or disrupted BMDC occur randomly. This effect is not a 
Leishmania antigen-specific feature of disrupted cells but rather the suppressive effect of 
Leishmania antigen lysate itself. This is supported by the in vivo data and the results of in 
vitro proliferation assay. These results demonstrated that disrupted antigen-loaded BMDC 
serve as a sufficient stimulus for protective immune responses as well as a source for 
antigen-specific T cell proliferation. 
 
 
4.4.3. Vaccination with disrupted antigen-loaded BMDC alters the cytokine 
response of splenocytes upon stimulation with Leishmania parasites 
The next step in our conventional animal experiments is the infection of the mice with 2 × 
105 Leishmania parasites into the right footpad one week post vaccination. Beginning 
from this point of time or shortly after, the immune response of the murine host should be 
transformed from a IL-4 and IL-10-driven Th2- response to an IFNγ and IL-12p70-driven 
Th1- response. To determine their cytokine response, splenocytes of mice vaccinated with 
the protective vaccine, i.e. sonicated antigen-loaded CpG-activated BMDC, were isolated 
one week post vaccination and stimulated with either PBS, CpG or LPS as controls or 
Leishmania either viable [L. major] or dead [Lmag]. 
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As expected, splenocytes of BALB/c mice expressed dramatically elevated amounts of 
IFNγ one week after vaccination [first pair of bars, Fig. 21, IFNγ] compared to naïve 
splenocytes. But, after stimulation of these differently pre-treated splenocytes with lysed 
or viable Leishmania parasites enhanced IFNγ production has been observed [third and 
fourth pair of bars, Fig. 21, IFNγ]. This shows that these splenocytes are already pre-
stimulated towards a Th1-related phenotype by the vaccination with disrupted antigen-
loaded splenocytes. 
In addition, due to the enhanced production of IL-2 by vaccinated splenocytes and the 
evidence for antigen-specific T cell proliferation shown in Fig. 18, we assumed a Th1-
related T cell proliferation initiated by the vaccination with disrupted antigen-loaded 
BMDC. In addition, this effect is dependent on the antigen-specific stimulus of disrupted 
BMDC used for vaccination as naïve and pre-stimulated splenocytes do not respond on 
CpG or LPS with expression of IL-2. Nevertheless,  elevated amounts of IL-6 and IL-10 
were observed. 
 
 
Results   
 
 
74 
 
 
 
 
Fig. 21: Cytokine production of naïve and vaccinated splenocytes after stimulation with Leishmania 
parasites. Single-cell suspensions of spleens were prepared from naïve BALB/c mice or mice which were 
vaccinated with sonicated Leishmania lysate-loaded CpG-activated BMDC. Cells were cultured and 
stimulated as indicated for 48 hours. Afterwards supernatants were collected and cytokine levels were 
determined via ELISA. T test p values: *, p < 0.05; **, p < 0.01; ***, p < 0.001. Data represent the mean ± 
SD of at least four independent experiments, except for IL-10. BMDC L+C, son.: sonicated Leishmania 
lysate-loaded CpG-activated BMDC; Lmag: Leishmania lysate; L. major: viable Leishmania promastigotes. 
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4.5. The protective principle of disrupted antigen-loaded BMDC is 
membrane associated 
 
4.5.1. Preparations of membranous particles derived from antigen-loaded BMDC 
serve as a protective vaccine against infections with L. major 
Solutions of disrupted antigen-loaded BMDC contain all molecules of viable antigen-
loaded BMDC. But, the integrity of plasma membranes is disrupted and cytosolic 
molecules loose their compartmentalisation by the surrounding plasma membrane and 
therefore become solubilised in the respective medium, either PBS or R-10. But still these 
solutions can serve as protective vaccines in animal studies as shown above. While taking 
a closer look at the mechanism of this DC-fragment-based vaccination strategy the 
question arose whether the immunity mediating effect of these solutions is associated with 
any distinct component of the disrupted cells. In consequence, we started to separate the 
aqueous phase containing all molecules that were solubilised during disruption and 
homogenisation from membranous particles via ultracentrifugation. After a washing step 
the resulting fractions, the membranous particles-containing pellet and the soluble 
molecules-containing aqueous phase, were resuspended used as vaccines in an animal 
experiment. Vaccination of mice with the membrane fraction of antigen-loaded BMDC 
mediated immunity against subsequent infections with L. major promastigotes in each 
individual mouse.  
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Additionally, Fig. 22 clearly demonstrates that the membrane fraction of antigen-loaded 
BMDC shows the same ability for providing protection against L .major as complete 
solutions of disrupted antigen-loaded BMDC, whereas the cytoplasmic fraction fails to 
confer protective immunity to these mice. 
In contrast to animal experiments described above, luciferase-expressing L. major 
promastigotes were used [luc2-L.major]  in  this  set  up.  After  administration  of  the  
respective substrate into mice the luminescence of viable parasites was detected with a 
CCD camera. Angela Bruder clearly demonstrated that parasite load in infected footpads 
and in draining lymph node show a good correlation with detected luminescence from 
infected footpads [A. Bruder, MD thesis, in preparation]. In consequence, comparison 
between relative light units emitted from infected footpads of protected vs. non-protected 
mice is expressed again as relative parasite load and therefore we were able to detect a 
Fig. 22: Monitoring of disease parameters after vaccination and subsequent infection with L. major. 
A: Development of footpad swelling after infection with L. major into the right footpad of mice which have 
been vaccinated as indicated. ANOVA p value < 0.0001; Dunnett’s post test: **, p ≤ 0.01. B: Determination 
of relative parasite load of the respective vaccination groups seven weeks post infection via measuring the 
luminescence emitted by luciferase expressing Leishmania. BMDC L+C, son.: sonicated Leishmania lysate-
loaded CpG-activated BMDC; supernatant or pellet respectively: supernatant or pellet after ultra-centrifugal 
processing of disrupted Leishmania lysate-loaded CpG-activated BMDC. The data shown are from a single 
experiment with five mice per vaccination group. 
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reduction of overall parasite load. Expression of cytokines by splenocytes or LN cells does 
not give a significant pattern that is assignable to protected or non-protected mice, except 
for  IL-12  that  is  expressed  in  higher  amounts  by  splenocytes  and  LN  cells  of  protected  
mice [see Fig. 23]. But, there is a tendency of LN cells of non-protected mice to express 
higher ratios of IFNγ : IL-10 without stimulation than LN cells of protected mice. In 
contrast, after stimulation LN cells of protected mice express higher ratios of IFNγ : IL-10 
than non-protected ones [see Fig. 24].  
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Fig. 23: Cytokine profiles of spleen and LN cells after challenge infection with L. major. Seven weeks 
post infection splenocytes and dLN cells of vaccinated mice were re-stimulated with Leishmania lysate. 
Supernatants were collected and cytokine levels of IL-4 [A], IL-6 [B], IL-10 [C] and IFNγ [D] were 
determined via ELISA. unstim.: without stimulation, open bars; lysate: re-stimulation with Leishmania 
lysate, black bars; BMDC L+C, son.: sonicated Leishmania lysate-loaded CpG-activated BMDC; 
supernatant or pellet respectively: supernatant or pellet after ultra-centrifugal processing of disrupted 
Leishmania lysate-loaded CpG-activated BMDC; n.d.: not detected. The data shown are from a single 
experiment with five mice per vaccination group. 
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4.5.2. In vitro analysis of cell fractions derived from antigen-loaded BMDC 
Fractions of antigen-loaded BMDC were tested in vitro to compare the immunogenic 
capacity of soluble and membrane fractions of antigen-loaded BMDC. Therefore, an 
analogous setting to the culture and the stimulation of splenocytes, as described above, 
was used. First, splenocytes of naïve mice were taken and stimulated with the respective 
cell suspensions or with PBS, CpG or LPS as controls.  
Regarding IFNγ, IL-2 and IL-6 the purified cytosolic and the purified membranous 
fraction showed almost equal immunostimulatory capacity like disrupted antigen-loaded 
BMDC. Contrary to our expectations raised as a consequence of the successful membrane 
fraction vaccine (see Fig. 22) and by previous experiments (see Fig. 20), no IL-12p40 and 
no IL-12p70 was detectable. Regarding effective vaccination, we have been able to detect 
clear differences between mice vaccinated with the aqueous fraction or membrane fraction 
(see Fig. 22). Here, only mice vaccinated with the pellet fraction were protected against L. 
major infections. In contrast, Fig. 25 does not show any differences in cytokine production 
Fig. 24: Ratio of IFNγ to IL-10 in the supernatants of spleen and LN cells 7 wk after footpad infection with 
L. major. Ratios of IFNγ to IL-10 in the supernatants were calculated from the cytokine levels detected by 
ELISA for   spleens  [A] and lymph nodes [B]. Where no cytokine was detected, the value of the detection 
threshold of the ELISA was used for calculating the ratio. 
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of splenocytes upon stimulation with either one of the two fractions. Low amounts of IL-2 
indicate a T cell proliferation-promoting milieu but again, there was no difference in IL-2 
production  after  the  respective  stimulus  either.  Therefore,  both  fractions  share  the  same  
adjuvant activity whereas the sufficient combination or the sufficient amount of antigen 
and adjuvant lies within the membranous fraction.  
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Fig. 25: Cytokine production of naïve splenocytes after stimulation with disrupted BMDC. Single-cell 
suspensions of spleens were prepared from naïve BALB/c mice. Cells were cultured for 48 hours with the 
respective stimuli. Afterwards supernatants were collected and cytokine levels were determined via ELISA. 
ANOVA p values: p < 0.0001 for IFNγ; p = 0.3193 for IL-2; p = 0.0005 for IL-6; p < 0.0001 for IL-12p40; 
p < 0.0001 for IL-12p70. Dunnett’s post test: *, p < 0.05; **, p < 0.01. Data represent the means ± SD of 
four independent experiments. supernatant or pellet respectively: supernatant or pellet after ultra-centrifugal 
processing of disrupted Leishmania lysate-loaded CpG-activated BMDC; n.t.: not tested.  
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Second, to investigate these observations further splenocytes of mice vaccinated either 
with the supernatant fraction or the pellet fraction were prepared and stimulated either 
with viable L. major promastigotes or Leishmania lysate. Again, controls were stimulated 
Fig. 26: Cytokine production of naïve and vaccinated splenocytes after stimulation with Leishmania 
parasites. Single-cell suspensions of spleens were prepared from mice which were vaccinated with the 
supernatant or the pellet-fraction of ultra-centrifugally processed Leishmania lysate-loaded CpG-activated 
BMDC. Cells were cultured and stimulated as indicated for 48 hours. Afterwards supernatants were collected 
and cytokine levels were determined via ELISA. p values: *, p < 0.05; **, p < 0.01. Data represent the mean 
± SD of four independent experiments, except for IL-10 [two independent experiments]. Lmag: Leishmania 
lysate; L. major: viable Leishmania promastigotes. 
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with PBS, CpG and LPS. Unfortunately, no substantial differences in the cytokine milieu 
expressed by the differentially stimulated populations have been observed (Fig. 26), but 
splenocytes of mice vaccinated with the pellet fraction showed statistically significant 
differences in their level of IL-2 production. This indicates the capability to induce T cell 
proliferation upon infection with L. major.  
 
 
4.5.3. Different immunostimulatory capability of purified fractions and complete 
fragments derived from antigen-loaded BMDC 
For the demonstration of vaccination efficacy or for the discovery of cell interactions 
modulating the immune response and control of disease development, the vaccination 
strategy using viable antigen-loaded DC is a very useful tool. For a widespread usage of 
an anti-leishmanial vaccine, a cheap and simple vaccination method with no need of 
cooling would be favored. Therefore, an effective vaccine of low complexity, like 
stabilized protein together with an adjuvant has great advantages over autologous cell 
therapy. To transfer the knowledge from bench towards bedside, essential components of 
antigen-adjuvant combinations have to be studied. The knowledge of their mode of action 
will lead the way towards the development of the desired vaccine. 
It was demonstrated that vaccination with Leishmania lysate alone did not induce 
protective immunity against Leishmania infections (61). This failure was due to 
inadequate immunostimulatory capacity of Leishmania lysate. In further experiments 
different cell types were used as shuttles for antigen. Using viable DC, disrupted DC and 
cellular fractions of these cells respectively, it was shown in vivo that elements of DC can 
serve as adjuvant for protective vaccination. In contrast, the model micro milieu did not 
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give identical images of what happens during vaccination or during pathogen encounter so 
far.  
To determine the relative cytokine production of splenocytes demonstrating the mode of 
immune stimulation of different vaccine formulations, comparative studies of splenocyte 
samples treated with Lmag or viable L. major were performed. For visualization, all data 
were transformed to a relative amount of secreted cytokines in comparison to the levels 
expressed by splenocytes of naïve mice [Fig. 27]. Slight differences in cytokine release 
between splenocytes of mice which were treated either with the aqueous fraction or with 
the membranous fraction have been observed, whereas only for IL-2 this difference is 
statistically significant. Pellet-pretreated splenocytes have the same bias for the release of 
IL-2 and IFNγ like splenocytes pretreated with disrupted antigen-loaded DC. However, it 
is clearly demonstrated that disrupted cells and purified cell fractions do have different 
immunostimulatory capacities. 
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Fig. 27: Relative cytokine secretion of splenocytes upon stimulation with L. major parasites. Relative 
cytokine expression was calculated from the previously shown data. Amount of cytokine release was set to 
one for naïve mice of both stimuli. Accordingly, the amount of cytokine secretion by splencytes of the other 
groups was calculated as a factor of one. Data represent means ± SD. Two-way ANOVA p values for pre-
treatments [column factor]: p < 0.0001 for IFNγ; p = 0.3193 for IL-2; p = 0.0034 for IL-6; p < 0.0001 for 
IL-10; p < 0.0001 for IL-12p40; p = 0.4577 for IL-12p70. Bonferroni’s post test: *, p < 0.05; **, p < 0.01, 
***, p < 0.001. Lmag: Leishmania lysate; L. major: viable Leishmania promastigotes; BMDC L+C, son.: 
sonicated Leishmania lysate-loaded CpG-activated BMDC; supernatant or pellet respectively: supernatant 
or pellet after ultra-centrifugal processing of disrupted Leishmania lysate-loaded CpG-activated BMDC. 
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5. Discussion 
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The present study demonstrates that intracellularly processed Leishmania parasites in 
combination with cell-derived fragments are able to induce protective immunity against L. 
major infections in otherwise susceptible BALB/c mice. Here, Leishmania antigen-loaded 
DC serve as the antigen processing machinery and later on - after disruption - as source of 
immune stimulatory molecules in combination with antigenic determinants. After i.v. 
injection, this formulation is taken up by host-derived DC which in turn induce antigen-
specific T cell proliferation, differentiation and activation and later on MΦ activation via 
initiation of IFNγ production. First, DC get activated during reception of the vaccine 
components and, second, produce co-stimulatory molecules and Th1-related cytokines for 
the proper stimulation of a protective immune response. Therefore, the protective effect of 
this vaccination is dependent neither on IL-12 production via the transferred DC nor by 
their type of MHC [H2-kb or H2-kd] or their activation status. These findings extend the 
knowledge of how to use DC for vaccination against intracellular pathogens and of what is 
necessary on a molecular level to prevent leishmaniasis in susceptible mice. 
 
First, earlier studies using viable antigen-loaded CpG-activated DC showed that there is 
no need of IL-12 production by the transferred cells (163). IL-12 is a potent inducer of 
Th1-based immune responses which are essential for the effective elimination of 
Leishmania parasites. In conclusion, other host-derived cells support the establishment of 
protective immunity [Fig. 28]. Second, DC-based vaccination is a time consuming and 
expensive procedure when curing or preventing human diseases. Preparation, expansion, 
antigen-loading and i.v. injection of human DC under GMP conditions is a huge effort that 
has to be made if treatment of lethal diseases like cancer is feasible. But, for worldwide 
preventive vaccination against infectious diseases this might be not practicable. Because 
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of these two reasons, it is necessary to focus on downstream events during the process of 
induction of preventive immunity for later simplification of the primary vaccine.  
 
To investigate the fate of injected viable DC these DC were stained with CFSE prior to 
injection. Consequently, it was able to find these cells or fragments of these cells in cryo-
sections  of  host  spleens  [see  chapter  4.2].  Additionally,  it  was  determined  that  DC  
fragments appear more often in the spleen than viable DC and these fragments are taken 
up by cells which locate in T cell rich areas. These finding were looked at more closely in 
parallel studies which are already published in Schnitzer et al., 2010 (181).  
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Fig. 28: Current paradigm of T cell activation after BMDC-based vaccination against leishmaniasis. 
I.v. injected BMDC provide antigenic peptides presented via MHC molecules together with co-stimulatory 
molecules for proper activation of T cells. Cytokines which are needed for directing the immune system 
towards a Th1-based immune response are provided from cellular sources of the recipient host. 
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Here it was shown that these fragments are taken up within the LAMP-1+ endosomal 
pathway of CD11c+ cells  [DC].  The  consequence  of  uptake  of  cellular  fragments  within  
the lysoendosomal pathway already was shown by Inaba et al. in 1998 (93). There, uptake 
and processing of cellular fragments led to the presentation of these antigens via MHC 
class  II  molecules.  Furthermore,  efficient  targeting  of  antigen  towards  the  LAMP-1+ 
endosomal pathway was shown to be an effective tool to enforce antigen presentation via 
MHC class I and II molecules (101). Therefore it was concluded that cellular material 
derived from i.v. injected DC is taken up by host DC in the spleen or is subsequently 
transported to the spleen by these DC. Afterwards it is presented via MHC molecules to T 
cells [and B cells with smaller degree]. Thus, DC still are the key players during 
protection  of  BALB/c  mice  from  otherwise  lethal  infections  with  L. major via initiating 
and guiding the adaptive immune response after vaccination with either viable or 
disrupted antigen-loaded DC. As a consequence for vaccine design, the target cell type 
stays the same. But now, in vivo host DC are the target for DC-based vaccination. 
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Nevertheless, direct interaction between transferred antigen-loaded DC and T cells in the 
spleen can not be ruled out in a setting where viable DC were transferred. This direct 
interaction still can be responsible for sufficient T cell activation and therefore uptake of 
transferred DC might be an artefact. The question which has to be addressed now is: Is 
direct contact between viable antigen-loaded DC and T cells needed for the induction of a 
Th1-based immune response? First answers to that question are given by experiments 
where PFA-fixed antigen-loaded DC were injected into BALB/c mice. Here, these cells 
still transfer protective immunity (181). More, it was revealed in this study that disrupted 
antigen-loaded DC show equal properties regarding establishment of protective immunity 
against subsequent infections with L. major, independent of the type of DC. Beyond this, 
the size of these disrupted cell fragments does not influence the efficacy of the vaccination 
which was shown by using different disrupting techniques. But, phospholipids of 
disrupted cell membranes tend to form vesicular structures (114). Kovar et al. clearly 
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Fig. 29: Classical paradigm of DC-based vaccination. The classical paradigm of DC-based vaccination 
proposes direct interaction of i.v. injected antigen-loaded and activated DC. All signals which are necessary 
for complete T cell activation, differentiation and proliferation are provided by these DC. 
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demonstrated that membranous vesicles which were derived from disrupted antigen-
loaded activated DC2.4 cells show the property of CD8+ T cell activation in vivo (110). 
Additionally, in vivo assays revealed that these vesicles interact directly with CD8+ T 
cells. In vivo these  vesicles  were  able  to  induce  anti-tumor  immunity  which  was  
accompanied by CD8+ T cell memory.  
 
 
 
 
The efficacy of disrupted DC as vaccines against Leishmania parasites together with the 
findings of Kovar et al. points towards a direct interaction of antigen-loaded CpG-
activated BMDC-derived fragments with the respective T cell population in naïve BALB/c 
mice that is able to induce protective immunity in these mice [Fig. 30]. Nevertheless, these 
findings contradict with the current DC-based vaccination paradigm which demands direct 
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Fig. 30: Possible mechanism of T cell activation via fragments of antigen-loaded CpG-activated 
BMDC. I.v. injected disrupted antigen-loaded CpG-activated BMDC provide antigenic peptides presented 
via MHC molecules together with co-stimulatory molecules for proper activation of T cells. Cytokines 
which are needed for directing the immune system towards a Th1-based immune response are provided from 
cellular sources of the recipient host. 
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interaction of viably transferred DC with T cells in vivo (61, 163). But in this experimental 
setup, it was clearly shown that no viable cells with intact metabolism or cellular integrity 
are needed for the transfer of activation stimuli together with antigen-specific 
determinants for the induction of protective immunity against subsequent infections with 
L. major. 
But, proper T cell activation - one of the principal mechanisms in immunology - demands 
both co-stimulatory molecules and antigen which has to be presented via MHC molecules 
to the respective T cell. Whether both are needed to be present in the respective 
formulations used here for vaccination against L. major was the next question that had to 
be addressed. For vaccines using viable BMDC it was known that activation via 
stimulation  with  CpG ODN is  a  prerequisite  for  vaccine  efficacy  (163).  In  contrast,  this  
holds not true for ex vivo prepared pDC and LC (61, 167). Furthermore, using disruption 
as pre-treatment prior to transfer activation of DC by CpG is neither a prerequisite for 
BMDC nor for in vivo grown pDC. In terms of reduced footpad swelling as well as 
parasite load in draining lymph nodes, mice which were vaccinated with one of these 
formulations showed full protection against subsequent infection with L. major parasites. 
If pre-existing co-stimulatory molecules like CD80/86 on the surface of transferred DC 
were necessary for effective T cell priming, there would have been the need of pre-
activation of BMDC. Reverse, stimulation of BMDC via CpG ODN, as done in earlier 
studies, could have led to enhanced uptake of transferred viable cells by host DC, whereas 
LC and pDC already showed good performance, respectively. As this is just a presumption 
without experimental evidence, it is still possible that dual mechanisms of T cell activation 
after vaccination with viable antigen-loaded CpG-activated BMDC account for the 
establishment of protective immunity against Leishmania parasites. Nevertheless, no co-
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stimulatory signal expressed by transferred DC is needed for the induction of protective 
immunity after transfer of disrupted antigen-loaded DC as a vaccine. 
On the one hand, the so far proposed mechanism of T cell activation via fragments of 
antigen-loaded DC utilizes direct interaction between T cells and these fragments. On the 
other hand, stimulation of T cells via co-stimulatory molecules [signal 2] and antigen 
presented by MHC class molecules [signal 1] is necessary for the direct activation of T 
cells.  But,  antigen-loaded  BMDC  do  not  have  efficient  amounts  of  co-stimulatory  
molecules unless they were treated with CpG ODN (163). Therefore, bystander help from 
surrounding cells would be necessary to complete the obligatory signals for T cell 
activation.  Only  signal  1  could  efficiently  be  presented  to  T  cells  by  disrupted  antigen-
loaded DC. Hence, the next question that had to be addressed was whether direct 
interaction is needed between disrupted antigen-loaded DC and T cells via antigen-MHC 
molecule-complexes and the respective T cell receptors.  
A simple way to do so is to bring MHC molecules on APC together with T cell receptors 
which were selected on a different MHC background. T cells exclusively can be activated 
by MHC class I or II molecules, respectively, which were present in the thymus during T 
cell development (28). In consequence, if there is direct interaction needed between these 
fragments  and  the  T  cells  then  there  will  be  only  activation  of  T  cells  if  DC were  used  
which share the same MHC background. In this study BALB/c mice were almost 
exclusively used for all of the experiments. These syngenic mice share the H2-kd type of 
MHC. In experimental setups, so-called Balb/b mice [data not shown] and C57BL/6 mice 
were used as donors for bone marrow and subsequently for BMDC. These mice share the 
H2-kb type  of  MHC.  Although  these  both  types  -  H2-kd and H2-kb - are different, 
fragments of antigen-loaded C57BL/6 BMDC were able to induce protective immunity in 
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BALB/c mice after i.v. injection. These mice showed a statistically significant reduction 
of footpad swelling together with a reduced parasite load in draining lymph nodes. This 
finding demonstrates that there is no direct interaction needed between the injected 
cellular fragment and the respective T cells. Or vice versa, host cells of the recipient mice 
have to fulfil this duty [Fig. 31]. 
 
 
 
 
Questions which might come up here are: How many of these fragments are taken up by 
host DC and how do these DC acquire the capability of full T cell activation?  
A simple answer to the first question is: Enough! The amount of disrupted DC which was 
used for vaccination of BALB/c mice resembles the cell number that was used for 
vaccination against Leishmania parasites with viable BMDC. These in vivo experiments 
clearly demonstrate that enough of these fragments are taken up by host DC to allow 
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Fig. 31: Proposed mechanism of T cell activation after DC-based vaccination against leishmaniasis. 
DC of recipient mice take up fragments of i.v. injected antigen-loaded DC which are the source of antigenic 
determinants. These antigens are subsequently presented in the spleen towards T cells which in turn become 
activated and start to proliferate. Therefore the induction of protective immunity is managed. 
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sufficient T cell stimulation. But if this uptake of these fragments by DC is somehow 
selective or targeted has to be elucidated in the future to provide a good basis for further 
development of the vaccine.  
As already mentioned, membrane particles of disrupted DC resemble exosome like 
structures and show comparable activity in terms of T cell activation and anti-tumor 
activity in in vivo models (110). Therefore, already known mechanisms and properties of 
exosomes could explain the good efficiency of DC fragment-based vaccination. In 
contrast to exosomes, vesicle formation after disruption is not a mechanism that allows a 
defined composition of membrane-bound or enclosed molecules. Anyhow, membrane-
bound molecules which were found on the surface of exosomes can account for the 
efficient uptake of injected cell fragments by host DC. Macrophage-1 antigen [Mac-1] 
(53), CD9 (99, 198) and milk fat globule-EGF factor 8 protein [MFG-E8/lactadherin] (78, 
212) have already been brought into relation with exosome uptake by DC. Additionally, 
membrane  vesicles  are  the  typical  prey  of  DC and  MΦ in  the  periphery  and  the  spleen.  
Very early after transfer, already 10 minutes post injection CD11c+ host cells can be found 
in the spleen, which took up labelled fragments of i.v. injected disrupted DC [Data not 
shown].  As  already  shown  (181),  PFA-fixed  DC  are  efficiently  taken  up  by  DC  of  the  
recipient  mice.  Fragments  of  these  PFA-fixed  DC  can  be  found  in  vesicles  which  are  
associated to the LAMP-1+ endolysosomal pathway and are therefore predetermined for 
efficient presentation via MHC molecules. Together with the here shown co-localization 
of  splenic  T  cells  and  DC  which  took  up  cellular  fragments  of  injected  BMDC,  these  
findings show a direct line which follows Leishmania antigen from loading of BMDC 
until presentation to host T cells [Fig. 31].  
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Unfortunately, splenocytes and LN cells of mice that were vaccinated and subsequently 
infected with L.major did not release consistent cytokine patterns. Nevertheless, protective 
vaccination with differently prepared disrupted antigen-loaded DC unequivocally resulted 
in reduced footpad swelling and reduced parasite load in draining lymph nodes [dLN] in 
comparison to PBS treated mice. 
 
 
 
 
But, to study this mechanism it was tried to set up in vivo assays which resemble the 
proposed  mechanism.  Cell  compositions  of  DC,  fragments  of  antigen-loaded  DC  and  T  
cells of primed mice did not show any activity in terms of T cell proliferation. These 
proliferation assays did not show reasonable data unless an undefined composition of 
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Fig. 32: Endocytosis of transferred DC fragments by host DC accompanied by subsequent activation. 
DC of  the  recipient  mice  take  up  fragments  of   i.v.  injected  antigen-loaded DC.  These  fragments  serve  as  
source for Leishmania antigen as well as of activating stimuli. The mechanism of host DC activation is not 
yet revealed. Support during activation may follow different pathways and may be initiated via several 
mechanisms. 
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splenic cells has been used to support the induction of T cell proliferation [see chapter 
4.4.1]. Then, antigen-specific T cell proliferation of CD4+ and CD8+ T cells was 
monitored. This combination of activated CD4+ and CD8+ T cells is needed as source of 
IFNγ after onset of disease (22, 42). Further more, whenever antigen-specific proliferation 
was seen it was accompanied by the production of IL-2 and high amounts of IFNγ. The 
supportive activity of splenic cells in this setting might be contact-dependent activation 
and release of DC activating cytokines by NK cells or other cell types (65, 152, 168). 
Nevertheless,  both  cell  types,  DC  and  NK  cells,  have  to  become  activated  via  certain  
stimuli. 
In experiments presented here [see chapter 4.5.1], suspensions of disrupted antigen-loaded 
DC were separated into the sedimenting membranous fraction and the soluble fraction. 
After i.v. injection of these fractions, only the membranous fraction was able to induce 
sufficient immunity against infections with L. major parasites. This data points towards 
membrane-bound stimuli on the surface of exosome-like vesicles which are responsible 
for DC activation. Additionally, DC disruption is maintained via crude methods. 
Exosome-like vesicles, which are formed after disruption of DC’s membranes, will 
resemble more or less vesicles of necrotic cells rather than those of apoptotic cells. More, 
it  is  well  known that  DC are  able  to  endocytose  necrotic  cell  debris  and  in  turn  become 
activated by danger-associated molecular patterns (62) like uric acid (186), High mobility 
group box protein 1 (133) and Hsp70 (12, 217). In consequence, exosome-like vesicles 
which originate from disrupted Leishmania antigen-loaded DC provide antigen for the 
activation of Leishmania-specific  T  cells  as  well  as  proper  signals  which  are  able  to  
induce DC maturation. 
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In order to develop a cell-based vaccine towards a rather simple composition of antigen, 
adjuvant and a good shuttle the efficiency and the molecular mechanisms have to be 
monitored quite closely during development. Therefore, the production and release of 
cytokines by splenic and lymphatic cells was assessed after termination of in vivo 
experiments and during several in vitro assays. 
Since several years it is known that Th1-related immune responses are necessary for the 
clearance of Leishmania parasites during acute infection (126). For the establishment of 
such a Th1-related immune response IL-12p70 and IFNγ are the key cytokines. IL-10 and 
IL-4 are the major opponents which might induce Th2-related immune responses or 
suppress Th1-related immune responses respectively. On account of this, splenocytes of 
naïve mice were looked at in vivo to monitor release of these four cytokines together with 
IL-6 and IL-12p40 upon stimulation with the different DC-based vaccines. Here, it is 
shown that disrupted CpG-activated BMDC already show Th1-stimulatory capacity 
independent of Leishmania antigen. Slight levels of IL12-p70 and IL-2 point towards 
induction of T cell proliferation and instruction of a Th1-related phenotype. This could 
lead to an unspecifically activated and pre-determined immune system which develops 
proper Th1-related immune responses against Leishmania parasites upon infection one 
week after vaccination. However, antigen-loading of BMDC is absolutely necessary for 
induction of antigen-specific T cell proliferation [see chapter 4.4.1]. Much more, 
vaccination with disrupted DC - without antigen-loading - and subsequent infection with 
L. major leads to exacerbation of the disease [see Fig. 12]. In the context of effective 
vaccination and induction of protective immunity against leishmaniasis with disrupted 
antigen-loaded DC this mixture of cytokines fits to the current paradigm of T cell 
activation via DC-based vaccination.  
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One step ahead, one week after successful vaccination the immune system of the 
respective mice has to face the Leishmania parasites. As it is predicted, for induction of a 
protective immune response the expansion of specific Th1 cells and the consequential 
production of IFNγ for the activation of MΦ is needed. Splenocytes of mice which were 
vaccinated with disrupted antigen-loaded CpG-activated BMDC produce exactly the right 
mixture of cytokines in vivo after stimulation with either viable parasites or crude 
Leishmania-antigen. Large amounts of IL-2 indicate T cell proliferation and high titres of 
IFNγ are able to induce MΦ-activation for the subsequent destruction of Leishmania 
parasites in the parasitophorus vacuoles (122). Increased levels of IL-6 suggest an 
inflammatory environment whereas IL-6 plays a dual role via immunosuppressive activity 
(226) as well as via anti-Treg activity (173). Surprisingly, elevated amounts of IL-10 were 
found. But, since a while IL-10-producing Leishmania-specific T cells are known (103). 
Beyond, recent studies give more evidence of IL-10 production in late stages of T. gondii 
or L. major infections (147). But, not the anticipated preformed Th2 cells or misguided 
naïve T cells that were directed to the Th2-related phenotype produced this Th1-opposing 
cytokine. Th1 cells release IL-10 in the context of immunoprotection, whenever an 
immune response has to be shut down. This gives a hint to a more complex role of IL-10, 
than it was proposed so far in the Th1/Th2-model. Overall, these two sets of data perfectly 
demonstrate the induction of antigen-specific T cell activation together with the 
establishment of a protective immune response to Leishmania parasites that is 
characterized by IL-12 production in the beginning of T cell priming and IFNγ production 
as activation stimulus for parasite killing by MΦ. 
Much more surprisingly, using the purified fractions of disrupted antigen-loaded CpG-
activated BMDC for stimulation of naïve splenocytes or vaccination of mice respectively 
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the  pattern  of  cytokines  did  not  show  this  perfect  emphasis  on  Th1-related cytokines. 
Although elevated, of IL-2 expression after stimulation with these fractions was not 
significantly hightened whereas a biological significance already was shown for the 
membranous fraction in in vivo experiments [see Fig. 22]. More, after stimulation of 
membranous fraction-primed splenocytes with Leishmania-antigen a clear up-regulation 
of IL-2 production can be seen, which points towards antigen-specific T cell activation 
and  proliferation.  But,  it  also  shows  the  immunostimulatory  capacity  of  the  soluble  
fraction, which resembles the cytokine release after stimulation with not-loaded disrupted 
BMDC [see Fig. 20]. Unfortunately, no significant amount of IL-12p70 was found in 
these co-cultures to complete the set of Th1-related cytokines during early T cell priming. 
Co-cultures of splenocytes from membranous fraction-primed mice lack the tremendous 
amounts of IFNγ after stimulation of splenocytes with Leishmania-antigen or viable 
parasites, although there is biological evidence from the in vivo experiments. However, 
these co-culture experiments have not been individually modified to let them generate 
comparable results. In fact, no significant concordance can be found between splenocytes 
of mice that were vaccinated with complete disrupted DC solution or the purified 
membranous fraction regarding Th1-related cytokine release [see Fig. 26]. 
During development and simplification of cell-based vaccines it is very important to 
monitor the efficacy of the vaccine as well as the consistency of molecular mechanisms 
which are involved in induction of immune responses, respectively. The origin, where this 
development for an anti-Leishmania vaccine was started, is an antigen-loaded CpG-
activated BMDC-based vaccine. Now we know that after disruption of these BMDC 
neither lack of CpG-mediated pre-activation nor different MHC background, nor 
purification via ultra centrifugation, nor exchange of BMDC for MΦ causes loss of 
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biological activity of this vaccine. Taking all this together, the basic composition of an 
effective vaccine would be the membranous part of cells - not necessarily autologous cells 
- which endocytosed sufficient amounts of Leishmania-antigen. However, regarding 
molecular mechanisms, these vaccine preparations differ in their ability to induce the 
release of Th1-related cytokines, at least in this in vivo model. Of course rather unexpected 
but, this is a good occasion to study the Th1/Th2 paradigm more in detail. Nevertheless, as 
biological efficacy ranks much higher than in vitro data, the here presented data clearly 
demonstrates the possibility of transforming classical cell-based vaccination strategies 
towards simple as well as effective vaccine formulations. 
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Dendritic cell-based vaccination is a well established technique for preventive and 
therapeutic instruction of the immune system where conservative vaccine formulations fail 
to cure or prevent diseases, respectively. Efficiency of this technique already was 
demonstrated in infectious diseases as well as for cancer in animal or human studies. Well 
controlled manipulation and antigen-loading of immature DC is most beneficial to this 
technique. But, time-consuming and cost-extensive procedures for preparation of DC 
precursors, expansion and stimulation of DC and inpatient administration are big 
disadvantages regarding vaccine development for pandemic infectious diseases that occur 
mainly in underdeveloped countries. Therefore vaccines are needed that are pathogen-
tailored and able to induce equal immune responses as their DC-based vaccine models. 
For vaccination against Leishmania parasites such a DC-based vaccine is feasible and its 
efficacy to induce protective Th1-based immune responses was already demonstrated in 
several animal studies. But, one of our own studies indicated supportive activity of host 
cells exceeding the allocation of T cells to become activated by transferred DC. IL-12, an 
important cytokine for the induction of Th1-related immune responses, has to be produced 
by  host  cells.  Therefore,  the  aim  of  this  study  was  to  investigate  the  mechanism  of  
BMDC-based vaccination with regard to simplification of the vaccine formulation. Key 
questions that have been addressed are: Which cells process the information that is 
transferred by the injected DC and what are the key components of this information? 
Further more, it was looked at whether altered vaccine formulations are able to induce 
protective immunity and whether they share equal molecular mechanisms. 
 
The current paradigm of BMDC-based vaccination proposes direct interaction of 
transferred BMDC with host T cells. These BMDC have to be antigen-loaded for 
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stimulation via antigen-peptide-MHC molecule-complexes and they have to be activated 
for proper co-stimulation of T cells.  Here,  this study demonstrates that  neither activation 
for co-stimulation nor direct interaction with adequate MHC molecules is needed for the 
induction of protective immunity against infection with Leishmania-parasites. 
Disrupted antigen-loaded BMDC are able to induce protective immunity in BALB/c mice 
without pre-stimulation via CpG ODN. Beyond, if BMDC were used with a different 
MHC-background than recipient mice then the vaccine still would be efficient in terms of 
reduction of footpad swelling and parasite load in draining lymph nodes. Even more, DC-
specific features are no key component that leads to protective immunity as vaccination 
with disrupted antigen-loaded MΦ shows equal properties than before mentioned vaccine 
formulations. Further more, it was found that host DC play a major role in transforming 
the incoming signal, received from transferred antigen-loaded DC, into Th1-related stimuli 
and Leishmania-antigen-specific T cell activation. 
Suspensions of disrupted antigen-loaded DC resemble a combination of laid off soluble 
molecules together with exosome-like vesicles that formed after disruption of membranes. 
Here it was shown that separation of the membranous and soluble fractions and 
subsequent transfer into BALB/c mice will lead to protection of these mice against 
infection with L. major promastigotes only if the membranous fraction is used as vaccine. 
More, this vaccine formulation takes advantage of easy storage at -80°C with no need of 
fresh production. This clearly demonstrates that the immunity-inducing principle of 
disrupted DC-based vaccination lies within the membrane enclosed fraction.  
On a molecular level, disrupted antigen-loaded DC induce Th1-related cytokines during 
vaccination and as response on pathogen encounter. In vivo assays revealed IL-12 
production and antigen-specific T cell proliferation among splenocytes that were 
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stimulated with disrupted antigen-loaded DC. Splenocytes of accordingly vaccinated mice 
produce tremendous amounts of IFNγ after stimulation with Leishmania parasites. In 
summary, disrupted antigen-loaded BMDC fulfil all characteristics of DC-based 
vaccination against Leishmania major. But, while purification of membranes of antigen-
loaded DC and subsequent transfer to BALB/c mice leads to control of the disease in the 
animal  model,  only  slight  levels  of  Th1-related cytokines are seen in the in vivo assays. 
Whether this points towards a loss of vaccine activity on unseen levels or unknown sites 
where Th1-related immunity is induced by both, complete solution and purified 
membranes, still has to be determined.  
 
Consequently, modifications of classical BMDC-based vaccines against infections with L. 
major have been found. These modified vaccines provide easier manufacturing procedures 
accompanied by statistically and biologically significant efficacy regarding prevention of 
leishmaniasis in BALB/c mice. Moreover, it was shown that a vaccine would be possible 
that does not have to consist of autologously prepared DC together with no need of pre-
activation.  
This study demonstrates the transformation of a DC-based vaccine against L. major into a 
convenient DC-targeted technique and can guide the way to affordable and efficient 
vaccines against leishmaniasis. 
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Die Impfung mittels Antigen-beladener dendritischer Zellen [DZ] ist mittlerweile eine gut 
etablierte Technik, die dann zum Einsatz kommt, wenn Standard-Impftechniken versagen, 
vor Krankheiten zu schützen beziehungsweise diese zu heilen. Die Effizienz dieser 
Technik konnte bereits für diverse Infektionskrankheiten und Krebserkrankungen in 
experimentellen Tiermodellen sowie am Menschen gezeigt werden. Hierbei ist die 
Möglichkeit zur wohldefinierten Manipulation und Antigenbeladung der DZ ein großer 
Vorteil gegenüber den konventionellen Ansätzen. Jedoch ist vor allem bei der Anwendung 
im klinischen Bereich die Präparation, Herstellung und Manipulation dieser autologen DZ 
mit einem erheblichen technischen, zeitlichen sowie finanziellen Aufwand verbunden. 
Hinsichtlich einer Präventivimpfung gegen eine pandemische Infektionskrankheit, die in 
hauptsächlich unterentwickelten Ländern vorkommt, wird dieser Aufwand sicherlich ein 
Hindernis darstellen. Daher muss für solche Fälle ein maßgeschneiderter Impfstoff 
entwickelt werden, der sich am Vorbild des effektiven DZ-basierten Impfstoffs orientiert. 
Für die Impfung gegen die Leishmania Parasiten besteht so ein DZ-basierter Impfstoff 
bereits. Dessen Wirkung, eine T-Zell Antwort vom Typ Th1 zu induzieren, wurde bereits 
in mehreren Veröffentlichungen demonstriert. Zusätzlich hat aber eine unserer Studien 
gezeigt, dass das typische Th1-bezogene Zytokin IL-12 zur Differenzierung naiver T-
Zellen nicht von den injizierten DZ bereitgestellt werden muss, sondern von der geimpften 
Maus. Dies gab erste Hinweise auf eine stärkere Beteiligung des Wirts-Immunsystems als 
zuvor angenommen.  
Daher sollte hier vertieft der Mechanismus dieser DZ-basierten Impfung untersucht 
werden, wobei modifizierte Impfstoff-Ansätze zum Einsatz kommen sollten. Dabei 
wurden die Fragen nach der vom Impfstoff transportierten Information und dem 
Empfänger dieser Information berücksichtigt. 
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Das aktuelle Paradigma zur DZ-basierten Impfung besagt, dass transferierte DZ im 
direkten Kontakt mittels dreier Signale T-Zellen stimulieren und aktivieren. Dafür müssen 
diese DZ mit dem entsprechenden Antigen beladen und aktiviert worden sein um das 
Antigen-Peptide mittels MHC Molekül im Kontext der Co-Stimulation präsentieren zu 
können. Jedoch zeigt diese Studie hier, dass weder eine Aktivierung der DZ noch die 
Präsentation des Antigens mittels passender MHC Moleküle notwendig ist für die 
Induktion einer protektiven Immunantwort gegen Leishmania Parasiten. 
Aufgeschlossene, mit Antigen beladene DZ müssen nicht vor dem Transfer mit CpG ODN 
aktiviert worden sein, um entsprechende Immunität zu verleihen. Ebenso hat der MHC 
Typ in diesem Falle auch keinen Einfluss auf die Effektivität des Impfstoffs. Da im 
Weiteren aufgeschlossene mit Leishmania-Antigen beladene Makrophagen nach Impfung 
die gleiche Wirkung erzielen, wie vorangegangene DZ-basierte Impfstoffe, können keine 
DZ spezifischen Mechanismen Schlüsselkomponenten der Induktion einer protektiven 
Immunität sein. Darüber hinaus konnte gezeigt werden, dass die DZ der geimpften Mäuse, 
eine maßgebliche Rolle bei der Verarbeitung transferierter Signale spielen. 
Suspensionen aufgeschlossener DZ stellen eine Kombination aus freigesetzten löslichen 
Molekülen sowie Membranvesikeln dar, die sich nach dem Aufschluss gebildet haben. 
Nach Auftrennung dieser beiden Fraktionen konnte gezeigt werden, dass ausschließlich 
die Membran-Fraktion nach Verimpfung eine geeignete Immunantwort zum Schutz vor 
Leishmania Parasiten induzieren kann. Als Vorteil dieser Aufreinigung erweist sich 
zudem die stabile Lagermöglichkeit bei -80°C. Somit ist klar gezeigt, dass die Immunität-
verleihende Einheit dieser Impfstoffvarianten in der Membran-Fraktion liegt.  
Verfolgt man die Induktion Th1-zugehöriger Zytokine in in vivo Experimenten so ergibt 
sich im Falle der Gesamtsuspension aufgeschlossener, mit Leishmania-Antigen beladener 
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DZ ein klares Bild. Diese Suspension erzeugt das volle Spektrum der DZ-basierten 
Impfung gegen Leishmania Parasiten. Es kann sowohl Produktion von IL-12 und IL-2 als 
auch eine antigenspezifische T-Zell Proliferation nach Stimulation von Splenozyten mit 
der entsprechenden Suspension verzeichnet werden. Außerdem produzieren Splenozyten 
von entsprechend geimpften Mäusen nach Stimulation mit Leishmania-Antigen erhebliche 
Mengen des entscheidenden Zytokins IFNγ. Obwohl jedoch die Verimpfung 
aufgereinigter Membranvesikel dieses Ansatzes im Tierversuch zu biologisch sowie 
statistisch signifikanten Ergebnissen führt, lassen sich die entsprechend Th1-bezogenen 
Zytokine im in vivo Ansatz nur in geringen Maße nachweisen. Ob dies jedoch für einen in 
vivo unbemerkten Aktivitätsverlust des Vakzins oder für andere lymphatische Organe als 
Ort der T-Zell Instruktion spricht, ist noch unbekannt und muss noch geklärt werden. 
 
Folglich konnten Abwandlungen des ursprünglichen und klassischen DZ-basierten 
Impfstoffes gegen Leishmania major gefunden werden, die sowohl Vorteile in der 
Herstellung  bzw.  Lagerung  als  auch  BALB/c  Mäusen  gleichwertigen  Schutz  vor  
Leishmaniose bieten. Darüber hinaus konnte gezeigt werden, dass ein Impfstoff möglich 
wäre, der nicht aus autologen DZ herzustellen wäre und dementsprechend auch keine 
Voraktivierung benötigt. 
Somit ist die Möglichkeit gegeben aus dem DZ-basierten Impfstoff eine einfache und 
effektive Technik zur Herstellung eines auf DZ abgestimmten Impfstoffes abzuleiten. 
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9.1. Abbreviations 
 
Ab     Antibody 
APC     Antigen-presenting cell 
BMDC   Bone marrow-derived dendritic cell 
BSA     Bovine serum albumin 
CD    cluster of differentiation 
CD40L  CD40 ligand 
cDC    conventional DC 
CL     Cutaneous leishmaniasis 
CpG ODN   CpG-containing olygodeoxynucleotide 
CTL     Cytotoxic T lymphocyte 
DC     Dendritic cell 
DCL     Diffuse cutaneous leishmaniasis 
DNA    Deoxyribonucleic acid 
dLN    Draining lymph node 
ELISA   Enzyme-linked immunosorbent assay 
FACS    Fluorescence-activated cell sorting 
FCS     Fetal calf serum 
FITC     Fluorescein isothiocyanate 
Flt3-L    FMS-related tyrosine kinase 3 ligand 
GM-CSF    Granulocyte/macrophage colony-stimulating factor 
HSP    Heat shock protein 
IFN     Interferon 
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Ig     Immune globulin 
IL     Interleukin 
iNOS    inducible NOS 
i.p.    Intraperitoneal 
IPC    type I interferon producing cell 
i.v.     Intravenous 
L.   Leishmania 
LmAg    L. major antigen 
LN     Lymph node 
LPS    Lipopolysaccharide 
LT    Lymphotoxin 
mAb     Monoclonal Ab 
mDC    myeloid DC 
MCL     Mucocutaneous leishmaniasis 
MHC     Major histocompatibility complex 
MΦ   Macrophage 
NK     Natural killer 
n.d.    Not detected 
NO    Nitric oxide 
NOS    NO synthase 
n.s.    not significant 
n.t.    not tested 
OD    Optical density 
PAMP   Pathogen-associated molecular patterns 
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PBS    Phosphate-buffered saline 
pDC     Precursor of DC 
PKDL    Post kala-azar dermal leishmaniasis 
PRR    Pattern recognition receptors 
s.c.     Subcutaneous 
SD    standard deviation 
SDS    Sodium dodecyl sulfate 
SDS-PAGE   SDS polyacrylamide gel electrophoresis 
son.    sonicated 
TCR    T cell receptor 
TGF     Tumor growth factor 
Th     T helper cell 
TLR     Toll-like receptor 
TNF     Tumor necrosis factor 
VL     Visceral leishmaniasis 
WHO    World health organization 
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